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To Nicole and Estelle, 
 
A person without a dream is a person,  
who will not be able to grow out wings. 
That person will never be able to fly. 
I want to see you fly.  
Fly and don’t let them ever wake you up from your dreams. 
There will be a lot of times that they will want to wake you up, 
Listen to your dad, in life only the dreamers are fully awake… 
     …Baba Nader 
 
 
  

  
ABSTRACT 
 
Lymphatic malformations (LMs) are structural defects in the lymphatic vessels.  
LMs are histologically benign lesions, however, due to localization, size and unexpected 
swelling, they may cause serious complications that threaten vital functions such as 
compression on the airways. A large swelling of the face or neck may also affect the 
esthetics and thus constitute a psychological strain for the patients and their families. LMs 
are also highly immunologically reactive and are prone to recurrent infections and 
inflammation causing pain as well as chronic oozing wounds.  
There are no available guidelines that describe management and follow up of LMs. Surgery 
has previously been considered the first treatment option. Surgery, however, has limitations 
as LMs often infiltrate adjacent structures, such as vessels and nerves making total 
resection difficult and potentially dangerous. Percutaneous sclerotherapy has replaced 
surgery as the primary treatment in most cases. Sclerotherapy also has limitations and can 
potentially cause serious complications such as unpredictable swelling that affects vital 
functions and cause scarring in the surrounding tissue.  
Review of the literature raises several questions. It is still unclear, which should be the 
treatment criteria for LMs and how to follow up the patients. LMs are rare conditions, 
however, our department has accumulated a large cohort of patients. No other institution 
has published a larger cohort of patients with LMs.  
 
The main objectives of this project was to evaluate the surgical- and interventional outcome 
of the treatment of LM patients, identify prognostic factors and better understand the 
inflammatory mechanisms of OK-432 treatment.  
 
In this dissertation the following research questions were addressed. 
1. Are there immunological pre-requisites that can be analyzed in a blood sample that 
provide prognostic information on the outcome of sclerotherapy using OK-432? 
2. How good is the long-term clinical outcome and the health-related quality of life of 
patients treated with sclerotherapy using OK-432? 
3. Is it possible to establish a treatment algorithm for patients with LMs involving the 
mediastinum by evaluating the current management with both surgery and 
sclerotherapy? 
  
In Paper I the hypothesis was that Toll-like receptor (TLR) expression in monocytes after 
treatment with the TLR4-ligand lipopolysaccharide (LPS) could be used to predict 
successful OK-432 treatment. Blood was analyzed from children with low response (LR, n 
= 6) and high response (HR, n = 5) to previous OK-432 sclerotherapy. Monocytes were 
stimulated with LPS. TLR4 expression was analyzed with fluorescence-activated cell 
sorting (mean fluorescence intensity (MFI)). The mean TLR4 upregulation after LPS 
stimulation was 3.6 times higher in the HR group than in the LR group and non-stimulated 
controls (P = 0.037). Dynamic TLR4 expression most probably represents a predictive 
parameter for the treatment of LMs with OK-432. In Paper II, further analysis showed that 
the mean expression of TLR 4 after LPS stimulation was comparable in both groups (HR 
1142 ± 652 units, LR 839 ± 427 units, P = 0.85). The pre-stimulation values in the LR 
group compared with the HR group were 950 ± 718 vs. 477 ± 341 with considerable 
differences of the mean expression changes after LPS stimulation (HR 665±683vs.LR 
111±605,P=0.08). The difference in TLR4 upregulation on monocytes after LPS 
stimulation in the LR group compared with the HR group can be explained by TLR pre-
conditioning. The findings suggest that absolute threshold values of TLR 4 could be a 
predictive parameter for the treatment of LMs with OK-432. 
In Paper III demographic data and long-term outcome in patients with LMs treated with 
OK-432 were analyzed. We enrolled 131 of 138 eligible patients treated with OK-432 for 
LMs between 1998 and 2013 in a retrospective study. The outcome was assessed with a 
clinical examination, evaluated with a clinical assessment score (CAS), and a questionnaire. 
LMs were localized to the head/neck (60%), the trunk (20%) and the extremities (6%) or 
involved more than one region (14%). Patients with microcystic (10%), macrocystic (21%) 
and mixed lymphatic malformations (69%) underwent a median number of three, two and 
two injection treatments, respectively. OK-432 treatment resulted in a successful outcome 
in 70% of patients with LMs. The long-term outcome was comparable to the short-term 
outcome. The number of injections, previous treatment and lesion localization predicted the 
clinical outcome. Four unsatisfactory attempts of sclerotherapy were shown to be a 
breakpoint for surgery. 
In Paper IV the management of patients with LMs involving the mediastinum was 
reviewed and a treatment algorithm was suggested. All patients with LMs involving the 
  
mediastinum between 2009-2015 at our institution were reviewed. We collected 
demographic data, data on investigations, management, and complications of the treatment, 
as well as outcomes at follow-up. Complications were described according to the Clavien-
Dindo classification. The patients treated with sclerotherapy and the operated patients had 
comparable numbers of Clavien-Dindo grade I-II complications. Clavien-Dindo grade III-
IV complications were five times more frequent after sclerotherapy than after surgery. The 
clinical outcome was excellent for the operated patients and fair to good for the patients 
receiving only sclerotherapy. Patients with cervical LM involving the mediastinum 
represent a high-risk group with respect to the severity of complications following 
sclerotherapy. Surgical resection of the LM in the mediastinum is recommended, with the 
possibility of intra-operative sclerotherapy as an adjunctive. 
In Paper V the health-related quality of life (HRQOL) was assessed in the cohort of Swedish 
children and adolescents with LMs who underwent injection treatment with OK-432 at our 
institution between 1998 and 2013. A study-specific questionnaire was sent to all patients 
with at least five years’ follow up after the first injection treatment asking for persisting 
symptoms and satisfaction with the treatment and care. KIDSCREEN-52 was used to assess 
HRQOL. Patients with LMs localized in the head and neck area and repeated sclerotherapy 
constitute a risk for negatively affected HRQOL.  
 
 
 
  
LIST OF SCIENTIFIC PAPERS 
 
 
I. Reismann M, Ghaffarpour N, Luvall E, Jirmo AC, Winqvist O, 
Radtke J, Wester T, Claesson G. Dynamic Toll-like receptor expression 
predicts outcome of sclerotherapy for lymphatic malformations with 
OK-432 in children. 
J Surg Res. 2014 Mar;187(1):197-201.  
 
II. Reismann M, Ghaffarpour N, Luvall E, Jirmo A, Radtke J, Claesson 
G, Wester T. TLR4 preconditioning is associated with low success of 
OK-432 treatment for lymphatic malformations in children.                                                               
Pediatr Surg Int, 2016 May:32(5):435-8 
 
III. Ghaffarpour N, Petrini B, Svensson LA, Boman K, Wester T, 
Claesson G. Patients with lymphaticmalformations who receive the 
immunostimulant OK-432 experience excellent long-term outcomes.                                                               
Acta Paediatrica 9 June 2015,104:1169–1173 
 
IV. Ghaffarpour N, Mesas Burgos C, Wester T.                                                       
Surgical excision is the treatment of choice for cervical lymphatic 
malformations with mediastinal expansion.                                                                                                        
J Pediatr Surg (2017) Avaliable online  
 
V. Ghaffarpour N, Claesson G, Wester T, Boman  K.                                                  
Long-term Health Related Quality of Life in a Cohort of Swedish 
Children with Lymphatic Malformations Treated with Sclerotherapy.  
 JAMA Pediatrics (2018) Submitted 
 
  
 
 
CONTENTS 
1 Prologue .......................................................................................................................... 1 
1.1 Historical reflections ............................................................................................ 2 
2 Introduction ..................................................................................................................... 4 
Vascular embryology ........................................................................................... 4 
Lymphangiogenesis ............................................................................................. 5 
The role of the lymphatic system ......................................................................... 7 
Formation of vascular malformations .................................................................. 9 
Classification of vascular anomalies ................................................................... 9 
Lymphatic malformations .................................................................................. 12 
2.1 Clinical presentation ........................................................................................... 13 
2.2 Investigation ....................................................................................................... 16 
2.3 Management ....................................................................................................... 18 
2.4 OK-432 ............................................................................................................... 21 
2.5 Outcome measures ............................................................................................. 24 
3 Aims .............................................................................................................................. 27 
Aims of the thesis ............................................................................................... 27 
Aims of the specific studies ............................................................................... 27 
4 Summary of the studies ................................................................................................ 28 
4.1 Patient and methods ........................................................................................... 28 
Analysis of TLR expression on monocytes (Paper I and II) ............................. 28 
Patient demographics and clinical assessment (Paper III) ................................ 30 
Assessment of complications of sclerotherapy and surgery (Paper IV) ........... 31 
Assessment of HRQOL in patients with LM (Paper V) ................................... 34 
Statistics ............................................................................................................. 35 
4.2 Results ................................................................................................................ 37 
Expression of TLR4 on monocytes after cell stimulation (Paper I and II) ....... 37 
Characteristics of patients with LM and clinical outcome (Paper III) .............. 38 
Mediastinal LM, clinical outcome and complications (Paper IV) .................... 41 
HRQOL in patients with LM treated with OK-432 (Paper V) ......................... 46 
Table 7  Patient demographics and background data ........................................ 46 
4.3 Discussion ........................................................................................................... 50 
Dynamic Toll-like receptor expression predicts outcome of sclerotherapy 
for lymphatic malformations with OK-432 in children (Paper I and 
II) ............................................................................................................ 50 
Clinical outcome of patients with LM treated with OK-432 (Paper III) .......... 51 
Treatment algorithm for LM involving the mediastinum (Paper IV) ............... 53 
LM in the head-neck area that require several treatments are prone to have 
affected HRQOL (Paper V) ................................................................... 56 
4.4 Conclusions ........................................................................................................ 58 
Paper I and II ...................................................................................................... 58 
  
Paper III .............................................................................................................. 58 
Paper IV .............................................................................................................. 58 
Paper V ............................................................................................................... 59 
5. Future perspectives .......................................................................................................... 60 
5 Appendix ....................................................................................................................... 63 
Acknowledgements ............................................................................................................. 72 
6 Populärvetenskaplig sammanfattning på svenska ........................................................ 74 
7 References ..................................................................................................................... 79 
8 Paper I-V ....................................................................................................................... 85 
 
  
LIST OF ABBREVIATIONS 
ADL     Activity of Daily Living  
Ang1   Angiopoietin-1 
AVM   Arterio-Venous Malformation 
CAS   Clinical Assessment Score 
CM   Capillary Malformation  
CD14  Marker molecule on monocytes 
CI    Confidence Interval 
DIC     Disseminated Intravascular Coagulation  
D2-40     Podoplanin  
E12.5  Embryonic day 12.5  
EXIT   EX-Utero-Intrapartem Treatment- procedure 
FACS      Fluorescence-activated cell sorting 
HLA-DR   Human Leucocyte Antigen DR 
HR          High Responder 
HRQOL   Health-Related Quality Of Life 
ICU   Intensive Care Unit 
IFN-γ   Interferon gamma pro-inflammatory cytokines 
IL-10   Interleukin-10 pro-inflammatory cytokines  
IL-17A   Interleukin-17A pro-inflammatory cytokines 
ISSVA   International Society for the Study of Vascular Anomalies  
KIDSCREEN-52 HRQOL screening instrument 
LEC  Lymphatic Endothelial Cells 
LIC   Localized Intravascular Coagulopathy  
  
LM   Lymphatic Malformation  
TLR  Toll Like Receptor 
TLR4   Toll Like Receptor 4 
TLR7   Toll Like Receptor 7 
LPS     Lipo-Poly-Saccharide 
LR   Low Responders 
LYVE       LYmphatic VEssels Hyaluronan receptor 
Macro LM  Macro cystic Lymphatic Malformation 
Micro LM   Micro cystic Lymphatic Malformation 
Mixed LM   Mixed Lymphatic Malformation 
MFI     Mean Fluorescence Intensity  
MRI     Magnetic Resonance Imaging  
mTOR  Mechanistic target of rapamycin 
NSVA   Nordic Society for the study of Vascular Anomalies 
NICU   Neonatal Intensive Care Unit 
OK-432  Picibanil    
p-value  Probability value  
PDGF   Platelet-Derived Growth Factor 
PDGF-R   Platelet-Derived Growth Factor receptor 
PICU   Pediatric Intensive Care Unit 
PIK3CA   Gene coding for the enzyme PI3K 
Prox1  Homebox gene 
RASA1  Gene coding for Protein activation 
SD         Standard Deviation  
SEM      Standard Error of the Mean  
S1P   Sphingosine-1-Phosphate 
Tie 1 and Tie 2 Angiopoetin receptors 
TGFb   Transforming Growth Factor beta 
TGFbR   Transforming Growth Factor beta Receptor 
VascERN   Vascular European Reference Network 
VEGF   Vascular Endothelial Growth Factor  
VEGF-R   Vascular Endothelial Growth Factor Receptor 
VM   Venous Malformation  
WHO   World Health Organization 
  1 
1 PROLOGUE 
 
The field of vascular anomalies and lymphatic malformations needs to be further explored. 
Vascular anomalies represent a spectrum of disorders from a simple “birthmark” to life- 
threatening entities. Patients with these anomalies commonly experience misdiagnoses due 
to confusion in the nomenclature. Accurate diagnosis is crucial for appropriate evaluation 
and management, which often requires a multidisciplinary approach. 
At the Department of Pediatric Surgery at Karolinska University Hospital, we have been 
faced with this demanding group of patients for many years. Our largest experience over 
the years concerning patients with vascular anomalies has been patients with lymphatic 
malformations (LMs). This doctoral thesis is focused on LMs. The objective was to better 
understand these complex malformations and evaluate the management. 
 
Prior to launching of this project we had some general philosophical and ethical 
considerations.  First of all, the number of subjects is limited due to the fact that this is a 
rare condition. The philosophical question whether it is ethically correct to study such a 
small field, when the possible benefit from the study will affect such a limited number of 
individuals, may be mandated. This is a matter of utilitaristic considerations whether the 
benefit of all science should aim at the good of all mankind or if the good of the individual 
is good enough. From one aspect we all share the same resources and we should aim to use 
our resources for the best of as many as possible. The other aspect is that we have a 
responsibility to try to handle the suffering of minorities and the ones with weak voices. 
Second, we have to bear in mind that we may find correlations between individual risk 
factors, potential co-morbidity, and mortality. This fact is also a matter of philosophical and 
ethical reflections. It is a balance between the good in finding a reason to intervene and 
protect an individual against a hazardous event in the future and the principle of autonomy 
where a person may not want to know about future events. A third general matter to 
consider is that the cohort consists mostly of children. Children are a vulnerable group of 
patients with somewhat limited possibilities to take part in a study and give an autonomous 
approval to a study in a written informed consent. Small children up to a certain age will 
have their legal guardians who will give their approval for the child to participate in a 
study. Mature children and grown-ups will give approval by themselves. The group of 
patients in between are the most problematic, when asked to participate in scientific studies. 
The legal age in Sweden when a child is heard is twelve, however, children much younger 
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than twelve have the right to protect their individual principle of autonomy themselves. The 
possibility of a child participating in a study due to the will of the doctor or the parents 
must be taken into consideration and the child’s rights should be protected.  
The Regional Ethics Review Board in Stockholm approved the studies in this thesis. To the 
best of my knowledge we have conducted our studies based on solid ethical and scientific 
foundations. 
 
1.1 HISTORICAL REFLECTIONS 
Throughout the history and in all cultures birthmarks have had mythological and superstitious 
explanations. The take on these congenital spots vary from good and luck bringing to being a 
very bad stigma for the affected individual. Many societies once believed that a pregnant 
woman's behavior could cause birthmarks. Some believe that eating too many red foods 
caused strawberry marks. Others believe that strong fearful emotions or overwhelming 
desires of a mother imprinted the marks. In some cases, people believe that the marks indicate 
an area where a person was injured in a previous life. In Iranian lore, it is thought that if a 
woman touches her belly as she watches a solar eclipse, her baby will be born with a 
birthmark. Some interpretations of birthmarks are more insidious. People with birthmarks 
have been cast out of normal society and demonized as witches because they were born with 
the "devil's mark." Fortunately, not all birthmark legends have such negative connotations; in 
some eastern European countries, it's considered good luck to touch someone with a 
birthmark. But even without superstitions and myths adding to the confusion, birthmarks 
often come with heavy emotional baggage. Many people ridicule children with disfiguring 
birthmarks, leaving psychological wounds much deeper than the marks themselves.  
All since the 17-th century individuals with congenital disfigurements have been humiliated 
in organized freak shows to amuse the crowds. One example, commonly known, is Joseph 
Merrick, “The Elephant man” (Fig 1), who probably had Proteus syndrome with 
disfigurement caused by vascular anomalies. Another example may be Quasimodo, the 
character from the Novel “The Hunchback from Notre Dame” written by the novelist Victor 
Hugo, who describes an individual who probably had LMs on his face and back. These 
individuals have been ridiculed and humiliated in circus shows due to their congenital 
malformations and in between the exposures they have been hidden from society and 
abandoned by their families [1]. 
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Fig 1 Fannie Mills ” The Ohio Big Foot Girl”, and ” John Merrick ”The elephant man” two persons who have 
suffered the humiliation of being objects in side-shows due to congenital malformations[2]. 
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2 INTRODUCTION 
LMs are rare anomalies of the lymphatic vessels. In order to improve and develop the 
management of LMs it is essential to understand the mechanisms behind the pathophysiology 
and the clinical problems as well as the normal physiology and embryology. LMs are defined 
as structural defects due to abnormal embryonic or fetal development. The clinical problems 
are heterogeneous.  
 
Vascular embryology 
The initial stages of vascular development are best described by the terms vasculogenesis and 
angiogenesis. The two processes describe the formation of new vessels by mesodermal 
precursor cells (Fig 2)[3, 4]. Angioblasts migrate, to specific sites in the embryo, adhere to 
one another and form loose connections. Later, the vascular tree grows by sprouting, cell 
division, migration, and assembly of endothelial cells derived from preexisting vessels 
through a process termed angiogenesis[3]. 
 
 
Fig 2 New blood vessel formation occurs via vasculogenesis and angiogenesis[5]. 
 
The molecular mechanisms that control the development of the vascular system are partly 
unraveled[6, 7]. 
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The vascular endothelial growth factor (VEGF) and the corresponding receptor VEGF-R 
seem to play a crucial role in the early phase of the vasculogenesis, whereas another family 
of vascular endothelial growth factors (Angiopoietins) and their receptors, Tie1 and Tie2, 
appear to play a latter role by controlling the sprouting, remodeling, and maturation of the 
developing vasculature (Gale and Yancopoulos, 1999)[7] (Fig3). 
 
 
Fig 3 Schematic representation of vascular formation and the role of the growth factors during vasculogenesis 
and angiogenesis[5].  
Lymphangiogenesis 
Lymphangiogenesis is the development of lymphatic vessels (Fig 4). The mechanisms 
controlling the development of the lymphatic vascular system are largely unknown. The 
lymphatic vessels form, like the blood vessels, from hemangioblastic stem cells. The first 
signs of developing lymph nodes are found already in the 5th gestational week[8, 9]. 
The lymphatic system is a vascular network of thin walled capillaries and larger vessels 
lined by a continuous layer of endothelial cells that drain lymph from the tissue spaces of 
most organs and return it to the venous system for recirculation. The origin of the lymphatic 
vessels is still controversial. Historically, the most widely accepted view of lymphatic 
development is the one originally proposed by Sabin (1902, 1904)[10].  
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Sabin proposed that early in development isolated primitive lymph sacs originate from 
endothelial budding from the veins. Sabin’s model proposed that from these primary lymph 
sacs the peripheral lymphatic system then spreads by endothelial sprouting into the 
surrounding tissues and organs. (Sabin, 1902, 1904; Gray, 1985)[10]. A report of the 
vascular endothelial growth factor receptor-3 expression pattern (VEGFR-3) during murine 
development [11] has provided support for Sabin’s model of lymphatic development. At 
embryonic day 12.5 (E12.5), VEGFR-3 is expressed in developing venous and early 
lymphatic endothelia, and it appears to become largely restricted to lymphatic endothelium in 
the adult tissues[11]. 
These findings suggest that VEGFR-3 may play a role in the development of the lymphatic 
system. It has been demonstrated that the homeobox gene Prox1 is a specific marker of a 
subpopulation of endothelial cells that by budding and sprouting gives rise to the murine 
lymphatic system. These findings fully validate Sabin’s proposal of the venous origin of the 
primary lymph sacs (Sabin 1902, 1904). Lymphatic vessels are thought to originate from 
the venous system, and this process is critically regulated by Prox1 transcription factor[12]. 
This mutual embryological background of the venous and the lymphatic systems provide 
theoretical explanations to the clinical observations of malformations with venous as well 
as lymphatic components mixed in the malformed tissue. 
 
 
Fig 4 The first lymphatic endothelial cells (LECs) sprout from the embryonic veins, then migrate and form 
lymphatic sacs. Further steps of lymphangiogenic growth involve sprouting, branching, proliferation, 
differentiation and remodeling processes[13].  
  7 
 
The role of the lymphatic system  
The Swedish scientist, writer and professor of medicine at Uppsala University Olaus 
Rudbeck first described the lymphatic system in the seventeenth century. He described a 
watery fluid distributed in fine vessels throughout the body parallel to the blood vessels. The 
lymphatic system consists of lymphatic organs, a conducting network of lymphatic vessels, 
and the circulating lymph (Fig 5). The lymphatic vessels include the tubular vessels of the 
lymph capillaries, and the larger collecting vessels the right lymphatic duct and the thoracic 
duct. The lymph capillaries are mainly responsible for the absorption of interstitial fluid from 
the tissues, (Fig 5) while lymph vessels propel the absorbed fluid with smooth muscle 
contractions forward into the larger collecting ducts, where it ultimately returns to the 
bloodstream via one of the subclavian veins.  Through the network of capillaries and 
collecting lymphatic vessels from all parts of the body interstitial fluid is efficiently drained 
and extravasated fluid is transported, along with large proteins and antigens, back to the 
circulatory system. Numerous intraluminal valves in the vessels ensure a unidirectional flow 
of lymph without reflux. 
 
 
 
 
 
 
 
 8 
 
a 
  
b 
Fig 5 Schematic overview of the a interstitial (tissue) fluid (the lymph) surrounded by lymph capillaries and 
the[13] b lymphatic system including the lymphatic organs, the lymphatic vessels and the lymph nodes[14].  
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The main function of the lymphatic system is: 
1. To remove interstitial fluid including cellular waste products and cellular debris together 
with invading bacteria and large proteins from the peripheral tissues. 
2. To absorb and transport fatty acids and fat as chyle from the digestive system 
3. To transport antigen-presenting cells such as dendritic cells to the lymph nodes along 
with bacterial and viral debris where an immune response is stimulated and cytokines and 
interleukins are produced and transported to the circulation. 
 
Formation of vascular malformations 
The formation of vascular malformations is highly multi-factorial. However, VEGF is 
important for the vascular growth phase. It plays an essential role during the angiogenesis, 
initiating the sprouting and formation of new vessels. Folkman and Haudenschild first 
observed angiogenesis in vitro in 1980[15, 16]. 
Angiogenesis does not involve differentiation of the various endothelial cells, but rather the 
reorganization of an existing vascular network in response to some locally acting 
angiogenic factors. Whereas VEGF is important for the growth phase, transforming growth 
factor beta (TGF-β), platelet-derived growth factor (PDGF), angiopoietin-1 (Ang-1), and 
their respective receptors are essential for the stabilization phase. Errors in the early 
differentiation results in vessels devoid of pericytes which display several abnormalities, 
including endothelial hyper cellularity, vascular tortuosity and the formation of focal micro 
aneurysms, altered organization of endothelial cell junctions, increased vesicular transport, 
and leakage of plasma and blood cells[17]. 
 
Classification of vascular anomalies 
One of the major challenges in the field of vascular anomalies is the nomenclature. Vascular 
anomalies involve virtually all fields of medicine since they can occur in all parts of the body 
and in all organ systems. Considering the clinical complexity of these lesions it is important 
that all specialists use the same classification. The World Health Organization (WHO) 
classifications are generally considered as the reference classification for tumors and tumor-
like diseases. The WHO classification of skin vascular “tumors” is a nonhierarchical list of 
a series of different diseases, irrespective if the nature is tumor due to cellular proliferation, 
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malformation, reactive, or infectious. [18] 
The WHO classifications of soft tissue tumors is thus misleading and confusing[19]. 
The lack of consistency in the nomenclature makes it difficult for clinicians across 
specialties to communicate using a common language specific for each entity, and 
confusion in the naming of lesions creates inaccuracies in scientific advances. It also makes 
coding and statistical data about the prevalence and incidence of these lesions inaccurate. 
For centuries, vascular birthmarks were referred to by common names such as port-wine 
stains and strawberry marks. Several classifications of vascular anomalies are available; 
some are general classifications, and others deal with specific organs or tissues or only with 
vascular tumors or vascular malformations. In 1863, the father of modern histopathology    
R. Virchow described the histology of vascular nevi[20].  
The terms angioma simplex, angioma cavernosum and angioma racemosum were introduced 
and described the different forms of blood-filled vascular lesions depending on the size and 
form of the collecting vessels or channels. G. Wegener, a student of Virchow, refined the 
nomenclature. Wegener studied the lesions and described that some lesions were blood-filled 
and some were filled with lymph fluid[20]. 
At this point the classification described vascular lesions depending on fluid content in heme-
angioma and lymph-angioma. The subgroups simplex, cavernosum, and racemosum were 
suggested to describe the form of the collecting channels. This classification system was 
widely accepted. Still this nomenclature is used in many institutions and histo-pathology 
departments. The works done by Virchow and Wegener suggested that all these lesions were 
tumors, benign of origin, but nevertheless tumors, hence the suffix ¨–oma¨. The modern era 
of vascular anomalies started in 1982 when Mulliken and Glowacki showed that vascular 
lesions could clinically look similar, although the endothelial characteristics differed[21].  
The classification now divided vascular anomalies in two major fields, vascular tumors and 
vascular malformations. The tumors are structures derived from endothelial cell proliferation 
with an accelerated mitotic activity. They may be benign, intermediate, or malignant 
depending on the cellular behavior. Vascular malformations occur due to errors in 
morphogenesis of the vessel formation and exhibit normal mitotic activity of the endothelial 
cells. The morphogenesis of capillaries, arteries, veins, or lymphatics is deranged and the 
pooled fluid, whether blood or lymph fluid, is a result of collapsed, dysfunctional, malformed 
fluid conducting vessel structures. Depending on the dominating type of vessels within the 
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malformation the flow characteristics of the lesion differ from low-flow to high-flow. Low-
flow malformations are capillary malformations, venous malformations and lymphatic 
malformations and high-flow malformations are arterio-venous malformations and arterio-
venous fistulas. The lump in a malformation has no solid component.  
Another classification, the Hamburg classification, used vessel type as the basis of 
classification of vascular malformations. Each vessel type may present malformations 
within large vessels “truncular malformations” or “extratruncular malformations” 
composed by smaller vessels diffusely infiltrating and being intimately embedded in the 
host tissue. This distinction is clinically relevant, because “truncular” malformations seems 
to behave differently, and are more often associated with pulmonary embolism when 
affecting veins and with chylous effusion when affecting lymphatic vessels[22].  
The International Society for the Study of Vascular Anomalies (ISSVA) was founded in 
1992 and one of the main perspectives of the society is to achieve a uniform classification 
for vascular lesions that can be adopted by all involved specialities. 
The current and latest classification was accepted by ISSVA in 2014[23] (Fig 6).  
 
Fig 6 Schematic overview of 2014 ISSVA classification 
In the latest ISSVA classification, the Hamburg classification and the original classification 
of vascular anomalies initiated by Mulliken and co-workers in 1996 have been united. The 
malformations are classified according to the origin of the vessel, anatomical localization, 
length, diameter, valves, communication and the persistence of embryonic circulation. The 
genetic basis of many types of vascular malformations has been further explored and 
additional disease entities have been identified that need more precise classification rather 
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than generic headings such as capillary malformation (CM), venous malformation (VM), 
lymphatic malformation (LM) and arterio-venous malformation (AVM). In the latest 
classification mixed forms of the malformations has been more accurately recognized and 
listed[24]. The classification also recognizes a number of dysmorphic syndromes that are 
associated with vascular anomalies such as Klippel Trenaunay Syndrome, Parkes Weber 
Syndrome, Servelle Martorell Syndrome, Sturge Weber Syndrome, Maffucci Syndrome, 
Cloves Syndrome, Proteus Syndrome and Bannayan Riley Ruvalcaba syndrome[24]. 
 
Lymphatic malformations 
LMs are defined as structural defects that occur because of defective lymphangiogenesis [25].  
The incidence of these malformations is 1:6000 to 1:16.000 live births[26]. There are no 
sexual or ethnic predilections. Ninety-five percent of LMs are diagnosed before 2 years of 
age. Almost all affected individuals are children. However, occasionally the LM may not be 
clinically evident until adulthood[25, 27].  
The cause of LMs is multifactorial and the exact mechanism is unknown. In many patients 
genetic analysis of the malformed tissue reveals an activating mutation in the PIK3CA gene. 
This is a somatic, non-inherited, mutation engaging the lymphatic endothelial cells lining the 
malformation. PIK3CA is known to play a role in regulating cell growth by signaling 
through the PI3K/mTOR pathway[28, 29].  
It has also been shown that vascular dysmorphogenesis may be caused by an activating 
mutation in the receptor tyrosine kinase TIE2 and it may also be associated with RASA 1 
gene mutation[30, 31]. 
According to the ISSVA classification LMs are classified as a single vessel malformation, 
however, combined variants with other vessel structures occur frequently especially in 
combination with venous malformation since the two vessel types have mutual origin[11, 13].  
Histologically, LMs are composed  of  thin-walled  vascular  channels  lined  by 
a  single  layer  of  ﬂattened  endothelium. The endothelial cells of the LM are immunopositive for 
podoplanin (D2-40) and Lymphatic Vessels Hyaluronan receptor (LYVE)-1[32]. 
The lumen of the lymphatic cysts are filled with immunological active proteins and cells such as 
interleukines, cytokines, macrophages and lumphocytes[33].  
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The presence of immunological active proteins makes the lymphatic malformed tissue highly 
reactive. Blood can also fill the channels indicating spontaneous or traumatic intralesional bleeding 
or it may indicate  mixed form of veno-lymphatic malformation.  
 
2.1 CLINICAL PRESENTATION 
The pooled lymph within the malformation expand the affected tissue and causes the 
clinical symptoms of LMs. LMs may clinically present in a variety of forms, including 
cystic lymphatic lesions presented as slowly expanding lumps infiltrating the surrounding 
tissue, angiokeratoma, chylus leak conditions, osseous lesions, generalized systemic lesions 
part of syndromes or lymphedemas. LMs do not grow by endothelial proliferation, 
however, they get larger with the same growth pattern as the child. Hormonal changes, 
trauma, and bleeding may cause them to swell rapidly.  Syndromes such as Turner, 
Noonan, and trisomies are associated with intrauterine LMs. 
 
Usually LMs occur in one isolated area of the body as a subcutaneous lump, occasionally 
the malformation is more diffusely spread over larger areas of the body, which is then often 
referred to as lymphangiomatosis. Superficial, palpable LMs expand into deeper cavities in 
6% of the cases[34]. 
All these variants fit into three morphologic subtypes of LMs: Macrocystic, microcystic and 
mixed lesions (a mixture with both macro- and microcystic components). The specific 
symptoms and severity of LMs vary based on the size and specific location of the 
malformation. Macrocystic LMs generally form soft, large, translucent masses. When 
present in the subcutaneous tissue the overlying skin may have a bluish hue. Macrocystic 
LMs can potentially be extremely large, even large enough to obstruct the airway at 
delivery requiring an EXIT (EX-Utero-Intrapartem Treatment- Procedure to secure the 
airways prior to the delivery.  
Microcystic LMs may appear as several small, raised sacs (vesicles) on the skin that contain 
clear or bloody (hemorrhagic) fluid. They generally grow slowly, usually in proportion with 
a growing child. Microcystic lLMs can thicken or swell causing enlargement of 
surrounding soft tissue and bones. They can be found on any area of skin or mucous 
membrane.  
Seventy-five percent of the lesions occur in the head and neck region[35, 36]. 
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Histologically, LMs are benign, however depending on localization, size and potential 
swelling they may cause serious complications like airway compromise, visual disturbance, 
pain and motility dysfunction. When evident at birth, LMs tend to be soft, spongy, non-
tender masses.  
A large swelling in the face or neck may cause esthetic problems and may be a 
psychological burden to the patients and their families. LMs are highly immune-reactive 
and are prone to recurrent infections. When LMs become inflamed, they swell, and the skin 
in the involved area becomes red and warm. Recurrent infections or inflammations cause 
pain and disfigurement of the affected area. Large infected LMs may also present with 
septic shock as a massive and sudden auto-infusion of highly immunologically active 
proteins may occur when pooled infected lymph is shunted into the general circulation from 
within the infected LM.  
Some anatomical regions such as the mediastinum are of additional concern[37]. The 
mediastinum is a limited cavity with vital structures such as the airways, the large vessels 
and the heart that may be compressed resulting in a life-threatening complication as the LM 
expands. LMs affecting the gastrointestinal tract or pelvis can cause constipation, bladder 
obstruction, recurrent bowel infection or protein loss[38, 39].  
LMs may be associated with the hematological disorder, Localized Intravascular 
Coagulopathy (LIC) with elevated D-dimer and mild to moderate thrombocytopenia. The 
coagulopathy may progress to Disseminated Intravascular Coagulation (DIC) after trauma 
or surgery. 
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Fig 7 Macrocystic LM a clinical features, b MRI T2 weighted image of large fluid filled cysts,                         
c Ultrasound guided puncture of cysts and injection of OK-432, d Clinical outcome after one sclerotherapy 
session. 
 
Fig 8 Mixed LM with mediastinal expansion a clinical features at EXIT assisted delivery, b surgical 
debulking around the vital structures in the mediastinum and intraoperative sclerotherapy, c MRI T2 weighted 
image showing mixed LM with cysts expanding into the mediastinum compressing the heart and the left main 
bronchus d clinical outcome after stages surgeries and adjuvant sclerotherapies. 
a
b 
c	 d 
a	
b	 c	
d	
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Fig 9 Microcystic LM a Clinical features in the gluteal region, b After surgical debulking, c Intraoperative view 
after resection of micocystic LM, d MRI T2 weighted image showing microcystic LM. 
 
2.2 INVESTIGATION 
The diagnosis of LMs can often be made before birth using ultrasound. After birth, a 
diagnosis of a lymphatic malformation is made based on a physical examination along with 
a detailed patient history. Ultrasonography is the imaging modality of choice to start the 
investigation of vascular anomalies (Fig 10). With sonography the flow characteristics of the lesion is 
measured and the tissue content is evaluated. Many times sonography will give required information 
about the lesion and be diagnostic. Magnetic Resonance Imaging (MRI) is however the golden 
standard modality of investigation for vascular anomalies in general to determine the extent and type 
of LM[40, 41].  
a b	
c d	
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Fig 10 Investigation algorithm for vascular anomalies 
 
In radiology LMs have been categorized into three subtypes – macrocystic, microcystic, or 
mixed (a combination of the other two) [42](Fig 11). Macrocystic and microcystic LMs are 
differentiated by the size of the cysts that the malformation consists of. The macrocystic 
type is made up of a single or multiple fluid-filled cysts, which are all larger than 2 cm in 
diameter; the microcystic type is made up of smaller cysts or soft tissue enlargement 
without cyst formation. Most LMs have both macrocystic and microcystic portions[43].  
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Fig 11 Clinical appearance and corresponding type of LM, a Macrocystic, b Mixed and c Microcystic[42] 
 
Fine needle aspiration cytology is mandated to rule out differential diagnoses such as teratomas, other 
malignancies, pseudocysts from parynchymal organs, including ranulas from the salivary glands or 
remnants from brachial clefts. 
There are several specific markers available for lymphatic tissue such as D2-40, LYVE-1, PROX-1, 
desmoplakin and VEGF-C receptor VEGFR-3[32, 44].  
These markers can be stained for on tissue samples and examined in clinical practice if diagnostic 
difficulties occur. This is, however, rarely mandated. 
 
2.3 MANAGEMENT 
There is no available treatment algorithm for the management of LMs due the heterogenic 
presentation among patients. The essential strategy of the treatment of LMs is directed 
toward the specific symptoms that are apparent in each individual. Symptomatic treatment 
may be antibiotics as well as painkillers and anti-inflammatory medication. A curative 
treatment is not always possible and should not be sought necessarily as it may result in too 
excessive and potentially dangerous treatments. The evaluations of the patients is 
occasionally complex and require a multi-disciplinary approach involving the insight and 
a	
a	
b	
b	
c	
c	
c	
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experience of pediatricians, pediatric surgeons, plastic surgeons, ear-nose-throat specialists, 
radiologists and interventional radiologists among various other health care personnel and 
paramedics. The specific treatment and interventions vary depending on multiple factors 
such as type of LM (Macrocystic, microcystic, mixed), size and anatomical localization as 
well as the presence of certain symptoms such as pain, recurrent infections or oozing. 
Generally macrocystic LMs can be treated more effectively with better outcome no matter 
the choice of treatment. Microcystic and mixed LMs are more difficult to treat, often 
requiring staged and repeated treatments, both interventional as well as surgical. Regardless 
of treatment modality there is always a risk of recurrence when treating LMs and in some 
cases LMs treatment is symptomatic and requires life-long therapy. 
Rarely LMs may shrink and resolve spontaneously, this is probably induced infection in the 
malformation that has same effect on the cystic malformations as sclerotherapy.  
The main therapeutic options for LMs are watchful waiting, compression garments, 
percutaneous drainage, surgery, sclerotherapy, laser therapy, radiofrequency ablation, or 
medical therapy. These different treatment options may be used in various combinations. 
All treatment modalities aim for the same effect as to remove the spaces were lymph could 
be pooled in the malformed tissue. 
 
Watchful waiting is an excellent approach after the LM diagnosis is fully established, 
differential diagnoses are ruled out and the patient and the caretaker have received adequate 
information. Often watchful waiting is used in small LMs with few or limited symptoms or 
LMs in situations were the medical problem is not fully evaluated and time will add 
essential information prior to the decisions for medical or surgical interventions. 
Compression garments are the bases of the treatment in lymphedema and microcystic 
LMs. The malformation, often a limb is wrapped into compression dressings and the pooled 
lymph is gradually squeezed out from the malformed tissue. 
Percutaneous drainage is a limited procedure, which means that the fluid in the LM is 
drained through a catheter or an incision. Drainage is often used in emergency situations in 
order to debulk excessive cysts that expand and compress vital structures or functions. The 
treatment must be combined with sclerotherapy or surgery in order to prevent re-
accumulation of lymph in the cyst. 
Surgery has traditionally been regarded as the treatment of choice for LM[26, 36]. 
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However, these lesions sometimes present to the surgeon as challenging conditions. Although 
they are benign in most cases, they frequently, especially microcystic LMs, infiltrate adjacent 
structures, such as, vessels and nerves[26, 36]. 
This makes total resection difficult and potentially hazardous. Surgeons are often confronted 
with serious complications, such as bleeding, wound infection, wound healing problems, 
nerve damage and recurrence[26]. Large LMs often require staged excisions[35, 45-47]  
A multidisciplinary approach involving surgeons and interventional radiologists are often 
needed for complex LMs. The aim of surgery as treatment for LMs is to remove the lesion 
and regain function of an affected area and prevent disfiguring complications. Surgery is 
especially suitable if the LM is localized to one area of the body and if full excision may be 
performed without sacrifice of vital structures. Surgery has also advantages as part of a staged 
treatment strategy were sclerotherapy and surgery is combined to maximize debulking of the 
malformed tissue. With this strategy large areas may be reduced.  
Sclerotherapy is a procedure in which an irritant solution is injected directly into the LM. 
This solution causes scarring within the LM, which eventually leads to shrinking or 
collapse of the malformation. Percutaneous sclerotherapy has replaced surgery in most cases 
of macrocystic malformations. During the past 30 years, sclerotherapy has emerged as a 
promising alternative to surgical management for LMs in children[45, 48-52].  
Macrocystic LMs of moderate size can be easily treated with sclerotherapy. Sclerotherapy 
may require multiple sessions to be effective, especially in extensive malformations.  
Many agents have been used for this purpose; among others doxycycline, OK-432, dextrose, 
bleomycin, ethanol and interferon[52]. 
A systematic review of the literature on nonsurgical treatment of lymphatic malformations 
has been carried out. OK-432 and bleomycin sclerotherapy were the most commonly used 
substances. They showed that 43%, 95%CI (28.9-57%) of patients undergoing OK-432 
injections had a complete/excellent response; 23.5%, 95% CI (5.8-41.3%) had a good 
response; 16.9%, 95% CI (10.3–23.4%) had a fair/poor  response; and 15.4%, 95% CI (8.6–
22.2%) did not respond. In the bleomycin group the results were as follows: 35.2%, 
95% CI (15.7-54.6%) excellent; 37.1%, 95% CI (22-52.3%) good; 18.4%, 95% CI (2.7-
34.2%) fair/poor; and 11.6%, 95% CI (3.5-19.6%) no response. The literature strongly 
suggests that the majority of patients who undergo sclerotherapy with OK-432 or bleomycin as 
first-line therapy for head and neck LMs will achieve a good to excellent clinical response. 
Serious complications and the need to progress to surgical salvage were infrequent. Given the 
heterogeneity of the treatment protocols used and variable results obtained between studies, 
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there appears to be no clear consensus as to when sclerotherapy is indicated, what agents 
offer the most benefit, and how these agents should be administered for optimal results[48].  
 
Furthermore, the use of sclerosing agents sometimes causes scarring due to the penetration 
of adjacent tissues, to the extent that subsequent surgery is difficult or impossible. 
Disadvantages are the need for repeated injections, skin and soft tissue necrosis, blistering, 
and to some extent unpredictable swelling with the risk of causing obstruction of vital 
structures after discharge from the hospital.  
Although sclerotherapy for LMs is minimally invasive and often safe, complications may 
occur ranging from mild systematic symptoms such as fever and fatigue to local swelling 
causing compression to vital functions requiring prolonged intensive care. 
 
Laser therapy and radiofrequency ablation are techniques that energy is deployed in the 
tissue in order to destroy affected lymphatic vessel tissue and induce shrinkage. These 
techniques are best suited for superficial skin or mucosal LM[53].  
 
Medical therapy has recently gained additional attention. Sirolimus and Sildenafil can be 
used to treat both diffuse as well as localized LMs and are administrated orally. Sirolimus has 
been used in cancer treatment as well as for graft versus host prevention after organ 
transplantations for a long time. The use for LMs has just recently been recognized and 
promising reports have been published[54, 55]. Sirolimus acts as a mTOR inhibitor and 
targets the LM as it inhibits cell growth by targeting the PI3K/mTOR pathway[28, 54, 56]. 
Additional research is required to fully develop treatment protocols with understanding of 
treatment duration as well as long-term outcome and side effects. Sildenafil relaxes smooth 
muscles of the vessel walls, which leads to decreased fluid collection within the LM.  
 
 
2.4 OK-432 
Ogita et al. introduced the immune-stimulant OK-432 as sclerosant for the treatment of 
LMs in 1987. OK-432 was prepared from strains of Streptococcus pyogenes and was 
primarily certified as an adjuvant cancer therapy in 1975. OK-432 is based on 
Streptococcus pyogenes strains, which are pretreated with penicillin G and heat. This 
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treatment leads to the loss of the streptolysin S-production. The application leads to various 
immune-pharmacological reactions that cause tissue shrinkage[57, 58]. 
The application of OK-432 leads to various immune-pharmacologic events that cause 
shrinkage of the LM. Experiments with human blood has showed that only one of three 
individuals is a so called “high responder”, who is able to up-regulate TLR-7 receptor on 
the leucocytes after OK-432 exposure[59].  
OK-432 is acting as a TLR-4 receptor ligand and thus, the activation of TLR-4 will lead to an 
up-regulation of the TLR-7 receptor, this leads to an expression of sequentially regulatory 
and pro-inflammatory cytokines like IL-10, IFN-γ and IL-17A[60] (Fig 12). 
So called “low responders” produce only IFN-γ, which is just dependent on TLR-4 
expression without expression of TLR-7. The latter exhibits a limited immune answer to pro-
inflammatory stimulation with TLR-4 ligands[61] (Fig 12). 
 
 
Fig 12 Illustration of hypothesis in Paper I and II. TLR4-dependent up-regulation of TLR7 in monocytes of 
HRs leads to extensive immune reaction. Monocytes of LRs show a reduced immune reaction with limited 
cytokine production due to deficient TLR7 expression. 
 
Several authors have shown evidence that OK-432 sclerotherapy is a safe and effective 
method and it has been suggested to be the first line treatment for LMs [45, 51, 62]. 
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The long-term clinical outcome of patients treated with OK-432 has not been well described 
in large cohorts[58, 63, 64].  
The success rate after treatment of LMs with OK-432 varies from 40% to 80% and cannot be 
predicted. Even in the case of macrocystic disease where one expects a successful outcome, 
every fifth patient is treated unsuccessfully. Success is defined as size reduction by 
inflammatory shrinkage by at least 50 %.  Other factors than the type of LM must be 
involved. Furthermore, the use of sclerosing agents sometimes causes unpredictable scarring 
due to the penetration of adjacent tissues, to the extent that subsequent surgery is difficult or 
impossible. [40, 42, 45, 50, 58, 65, 66]. Prenatal anatomical characteristics may predict 
outcome. 
 
In spite of being feasible to treat LMs with OK-432 the patients show variable response to the 
treatment and occasionally the treatment is followed by significant swelling that can 
compromise vital functions such as the breathing. To what extend swelling follows the 
treatment is difficult to predict. The type of LM, microcystic, macrocystic, or mixed lesions, 
is often considered to be a prognostic factor for the outcome of sclerotherapy[67, 68]. 
Different outcomes in patients with the same type of lesion may indicate that individual 
factors have an influence on the response to the treatment. One explanation for the variation 
in clinical response to OK-432 treatment may be individual immune- pharmacological 
prerequisites[57, 58].  
Mediastinal LMs are of special concern and are prone to severe complications after 
sclerotherapy. Patients show variable response to OK-432 and occasionally the treatment is 
followed by significant swelling that can compromise vital functions such as the breathing. 
Lesions in the mediastinum represent a special challenge in this sense due to the narrow 
compartment with vital structures. A multidisciplinary team should always tailor the 
treatment of LMs for each patient individually and the potential risks for each treatment 
modality must be considered[48, 49].  
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2.5 OUTCOME MEASURES 
The clinical presentation and symptoms of LMs depend on type, size and location. The 
indications for treatment are individualized and differ within the group without clear 
treatment protocols making systematic assessment of outcomes challenging or impossible. A 
systematic meta-analysis on intra-lesional bleomycin injections for vascular malformations 
revealed that most authors use the size of the malformation and the shrinkage as the primary 
outcome measure[69]. Size is best evaluated with imaging techniques. To determine the exact 
shrinkage of the malformation after treatment imaging should be performed with the same 
modality as prior to the treatment. If the radiological work-up for LMs is done with MRI, the 
follow-up should be done with MRI. This is of course not practical as MRI often is an 
invasive investigation within the pediatric population, as it in many occasions requires fully 
anesthetized children and it is also expensive. Therefore, clinicians often estimate size and 
volume of the malformations prior and after treatments by subjective non-validated methods. 
Other outcome measures such as symptom relief, patient satisfaction or quality of life are 
difficult to find in the literature.  
Many therapeutic studies have been published, but the heterogeneity in outcome measures 
used to determine treatment success or failure makes it difficult to compare or combine 
results[70, 71]. 
There is a need for standardization of outcome measurement in clinical research studies of 
vascular malformations. Recently an international multicenter consensus study, (the 
Outcome measures for VAscular MAlformations project, OVAMA) suggested core 
outcome sets for clinical research on peripheral vascular malformations, including 
Lymphatic malformations (LM), Venous Malformations (VM) and ArterioVenous 
Malformations (AVM). In order to achieve that, an expert panel along with patients and 
parents agreed on what the most important outcome measure domains are for the largest 
subgroups of vascular malformations and how they should be measured. The core outcome 
measures for LM that were agreed on was the overall health related quality of life 
(HRQOL), the activity of daily living (ADL), recurrence, radiological assessment, overall 
severity of symptoms, pain, location specific signs and infections[72].  
 
HRQOL refers to the subset of quality of life directly related to an individual’s health, which 
as defined by the World Health Organization includes physical, mental, and social wellbeing.
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It has become an increasingly important outcome measure from the clinical and 
epidemiological point of view[73, 74].  
This development is a result of the understanding that ¨cure¨ is an insufficient goal of care, as 
optimal health should include physical, psychological, social and cultural dimensions of 
wellbeing and functioning[75]. 
Childhood illness, severe or chronic, may potentially affect quality of life. Therefore, 
increased attention is being paid to the impact of consequences of illness and treatment on   
quality of life of patients[76]. 
Studies have showed that patients with rare diseases, such as vascular anomalies, despite 
treatment outcome, have an increased risk of physical and psychological undesirable long-
term consequences[77-80]. 
HRQOL is sparsely studied in the literature in patients treated for LMs. In a Finnish study of 
long-term follow up after treatment of head/neck or trunk LMs, a subset of 26 patients were 
subject to an explorative quality of life survey. It was concluded that a majority of the 
patients did well after sclerotherapy[81]. 
The Clavien-Dindo classification is widely used to evaluate surgical complications and 
objectively grades complications after surgery in relation to the extent of treatment required 
to cope with the complications[82]. The Clavien-Dindo classification has previously been 
used for a systematic evaluation of complications after sclerotherapy on venous 
malformations[83]. 
In order to bring forward a treatment algorithm for patients with LMs it is essential to both 
measure and evaluate the clinical outcomes as well as assessing the complications to the 
various treatment using the same evaluation tool despite if the patients have been operated 
or received sclerotherapy. Clavien-Dindo classification to stratify the postoperative 
complications is widely used in surgery and provides an objective measure of the 
complications on a scale based on the severity[82].  
The need of antibiotics, pain relief, parenteral nutrition and blood transfusion are 
considered to be grade I-II complications. Grade III-IV complications are complications 
requiring surgery or radiological intervention and need of intensive care in general 
anesthesia. The Clavien-Dindo classification has been successfully used for a systematic 
evaluation of complications after sclerotherapy on venous malformations[83]. 
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The various treatment modalities for LM especially sclerotherapy may be evaluated 
concerning complications using Clavien-Dindo classification in order to be objectified and 
comparable.  
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3 AIMS  
 
Aims of the thesis 
The main objective of this project was to evaluate the outcomes of treatment of LMs, 
identify prognostic factors and better understand the inflammatory mechanisms of OK-432 
treatment.  
 
Aims of the specific studies 
1. To evaluate TLR4 expression as a tool to predict the outcome of OK-432 injection 
treatment in order to improve selection of patients for sclerotherapy (Paper I). 
 
2. To further investigate the immunological response of monocytes after LPS stimulation to 
understand why patients respond differently in spite of having a similar malformation 
(Paper II). 
 
3. To describe the demographics and long-term outcomes of a large cohort of patients with 
LMs managed with OK-432 sclerotherapy (Paper III).  
 
4. To evaluate predictive factors for the outcome of OK-432 sclerotherapy (Paper III). 
 
5. To review the management and outcomes of patients with LMs involving the 
mediastinum and to propose a treatment algorithm to guide the management of these 
rare malformations (Paper IV). 
 
6. To assess the complications after sclerotherapy as well as surgery for LM with the 
Clavien-Dindo classification (Paper IV). 
 
7. To assess the long-term HRQOL in a cohort of Swedish children and adolescents with 
LMs treated with sclerotherapy (Paper V). 
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4 SUMMARY OF THE STUDIES  
 
 
4.1 PATIENT AND METHODS 
 
Analysis of TLR expression on monocytes (Paper I and II)  
 
In Paper I and II we analyzed blood from eleven children with LMs. All children had been 
treated with OK-432. Five of the children had a good result (high responder, HR, n =5) of 
the treatment and six children insufficient result (low responder, LR, n =6) after treatment 
with OK-432. All children were assessed with clinical evaluation and with ultrasound to 
measure the size of the malformation. A good result was defined as shrinkage of >90% of 
the original size of the whole malformation. An insufficient result was shrinkage by <50%, 
which was considered to ensure a sufficient difference between the groups. Only patients 
with doubtless results were included in order to distinguish the groups clearly. The groups 
were established before the laboratory analysis and no change was performed thereafter. 
The blood samples were coded and a blinded analysis was performed.  
After harvesting the monocytes with pipettes the cells were suspended with 1% 
penicillin/streptomycin and each sample were split up in two fractions and incubated on at 
human body temperature.  One of the two fractions was incubated with the TLR-4 ligand, 
Lipo-Poly-Saccharide (LPS) for 20h. OK-432 is acting as a TLR-4 ligand but represents a 
combination of different substances with effects that are not fully defined. It could therefore 
not be used to selectively investigate effects of TLR4 binding.  
After the incubation time, the cells were harvested again and stained with antibody staining 
for identification of cells (monocytes), receptors (TLR) on the surface (TLR4) and 
intracellular (TLR7) identification. The isotype controls were treated exactly like the other 
samples.  
We used Fluorescence-activated cell sorting (FACS) (Fig 13) before and after LPS 
stimulation of the monocytes to detect the presence of TLR4 and TLR7 receptors on the 
surface of the cells. FACS is a useful scientific instrument as it provides fast, objective and 
quantitative recording of fluorescent signals from individual cells as well as physical 
separation of cells of particular interest.  
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Fig 13 FACS, TLR4 and 7 specific Fluorescence dye is used to stain the receptors on the surface of the cells. 
The fluorescence activity on the surface of the cells is measured with laser and the cells are also sorted based on 
the respective electromagnetic gradient[84].  
 
In Paper I we hypothesized that the immunological mechanism of OK-432 treatment was 
conducted through stimulation of TLR4 on the surface of the monocytes that will lead to an 
intracellular up-regulation of TLR7 and thus a much stronger inflammatory response on HR 
patients compared with LR patients.  
In Paper II we further analyzed the mean fluorescence intensity (MFI) and corrected by the 
fluorescence of the isotype controls (corrected MFI) (Fig 14). 
The absolute expressions of TLR4 in the HR and LR cells with and without LPS 
stimulation were investigated.  
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Fig 14 Gating protocol for identification of HLA-DRDCD14D monocytes. Analysis of TLR4 expression on 
monocytes in high- and low-responding patients (mean fluorescence intensity; gray filling, isotype control; 
continuous line, nonstimulated control; dotted line, sample after stimulation with LPS). 
 
 
Patient demographics and clinical assessment (Paper III) 
Paper III was a cross-sectional, observational study of 138 patients with LMs treated with 
OK-432 at the Astrid Lindgren Children´s Hospital, between 1998 and 2013. The final group 
for the study after exclusion due to loss to follow up consisted of 131 patients; 74 females and 
57 males. The malformations were categorized according to the ISSVA classification 
(International Society for the Study of Vascular Anomalies)[23]. All patients received OK-
432 (0.1 mg, in 10 ml NaCl solution) and the injection treatment was guided with 
ultrasonography. Injection therapy was repeated if the outcome was considered to be 
unsatisfactory at follow-up. The charts were retrospectively reviewed. The outcomes were 
assessed with clinical examination and a questionnaire. MRI is a well-recognized method for 
evaluating patients with LM after sclerotherapy. However, MRI is an invasive examination in 
pediatric patients, due to the need for general anesthesia, and it is also expensive. We chose to 
evaluate the patients clinically, using a clinical assessment scale (CAS) as a follow-up 
instrument (Table 1). The clinical outcome of the patients was assessed with the clinical 
assessment scale (CAS) that was tailored for clinical evaluation in Paper III. The last MRI 
was analyzed for postoperative or postsclerotherapy evidence of remaining LM in the 
mediastinum. 
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Clinical evaluation Result Score 
No remaining signs and symptoms Excellent 5 
Small palpable lumps or regress of mass > 50%, rarely 
symptomatic 
Good 4 
Larger palpable lumps or regress of mass < 50%, 
occasionally symptomatic 
Fair 3 
No regress of signs and symptoms Poor 2 
Worsening of signs and symptoms Worse 1 
 
Table 1 Clinical Assessment Scale (CAS) for clinical evaluation of LM 
 
Patient or parent satisfaction was estimated based on the questionnaire. The patient 
satisfaction scale in the questionnaire comprised a score of five for very satisfied, four for 
satisfied, three for acceptable, two for unsatisfied and one for very unsatisfied. The impact of 
11 variables on the clinical outcome was tested; age at symptom debut, time to confirmation 
of diagnosis, gender, lesion location, side, lesion type, estimated LM volume previous 
treatment with either resection or another type of sclerotherapy, number of OK-432 injection 
treatments, age at first treatment and more or less than five years of follow-up. These 
variables were chosen since they were systematically collectable in our records and also 
because we considered them to possibly affect HRQOL.  
 
Assessment of complications of sclerotherapy and surgery (Paper IV) 
In order to bring forward a treatment algorithm for patients with LM involving the 
mediastinum we needed to measure the clinical outcome and assess the complications of 
this group of patients using same evaluation tools both for the patients that have been 
operated as well as those who had received sclerotherapy. This was a cross-sectional, 
observational study. The charts were retrospectively reviewed of all patients with LMs 
involving the mediastinum treated at our institution between 2009 and 2015. We collected 
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demographic data; data on investigations, management, and complications of treatment, as 
well as outcomes at follow up. We used the Clavien-Dindo classification to stratify 
complications (Table 2). The need of antibiotics, pain relief, parenteral nutrition and blood 
transfusion was considered to be grade I-II complications. Grade III-IV complications were 
complications requiring surgery or radiological intervention and need for intensive care in 
general anesthesia. The need for mechanical ventilation more than eight days in the PICU 
after sclerotherapy was considered grade III complication.  The use of repeated 
sclerotherapy, without symptomatic relief in an intensive care patient, was considered a 
grade III complications and comparable with other radiological interventions. Each 
complication was counted in order to quantify complications per treatment.  
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Table 2 The Clavien-Dindo classification of surgical complications[82] 
 
 
 
 
Grade Clavien-Dindo Classification of Surgical 
Complications 
1 Any deviation from the normal postoperative course without the 
need for pharmacological treatment or surgical, endoscopic, and 
radiological interventions. Allowed therapeutic regimens are: 
drugs such as antiemetics, antipyretics, analgetics, diuretics, 
electrolytes, and physiotherapy. This grade also includes wound 
infections opened at the bedside. 
2 Requiring pharmacological treatment with drugs other than 
allowed for grade 1 complications. Blood transfusions and total 
parenteral nutrition are also included. 
3a Surgical, endoscopic, or radiological intervention without general 
anesthesia. 
3b Surgical, endoscopic, or radiological intervention with general 
anesthesia. 
4a Life-threatening complication requiring intermediate care or 
intensive care unit management, single organ dysfunction. 
4b Life-threatening complication requiring intermediate care or 
intensive care unit management, multi-organ dysfunction. 
5 Death of a patient. 
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Assessment of HRQOL in patients with LM (Paper V) 
All patients who underwent injection treatment with OK-432 for LMs at Karolinska 
University Hospital in Stockholm, Sweden, between 1998 and 2013 were retrospectively 
reviewed. The LMs were diagnosed by physical examination, ultrasonography and magnetic 
resonance imaging. Malformations were classified according to the International Society for 
the Study of Vascular Anomalies (ISSVA) classification based on the radiological 
appearance in macrocystic, microcystic or mixed LMs. The classification does not take the 
size of the malformation or the number of cysts into account. The lesions were also 
categorized according to the anatomical localization[85].  
A questionnaire was sent to all patients with at least five years’ follow up after the first 
injection treatment asking for persisting symptoms and satisfaction with the treatment and 
care. The KIDSCREEN-52 was used to assess HRQOL[73]. KIDSCREEN is a standardized 
tool for assessing children´s and adolescents´ subjective health and wellbeing[74].  
The KIDSCREEN was developed as a European cross-national cooperation providing 
validated data from 13 European countries. The dimensions covered by KIDSCREEN-52 are 
Physical Well-being, Psychological Well-being, Mood and Emotions, Self-perception, 
Autonomy, Parent Relations and Home life, Financial Resources, Social Support and Peers, 
School environment, and Bullying. 
The European validated general population norm data for KIDSCREEN cover the 8 to 18 
years' age range. Swedish validated norm data cover the 12-18 years span only. In this study 
we therefore used the European norm data as the reference for the entire group, while in 
addition Swedish norm values were used as the reference for the subgroup of 12-18 years old 
patients. 
A comprehensive study-specific questionnaire was also developed for this project. 
Information from that questionnaire was derived regarding patient-reported occurrence of 
persistent visible signs of illness/treatment (yes/no), and self-reported patient satisfaction with 
treatment (along a 5-grade Likert scale ranging from very satisfied to very dissatisfied). The 
treatment outcome was categorized on a six-step scale based on remaining signs of the 
malformation assessed on a clinical evaluation ranging from excellent to worse. For the 
statistical analysis the variable was dichotomized into 1 (the two best categories), and 2 (the 
four poorest categories). 
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Statistics 
Paper I-II 
Expressions of the TLRs in monocytes after stimulation with LPS were compared with 
expressions in nonstimulated cells (response ratio). Two tailed unpaired t-test statistical 
analysis was performed with GraphPad Prism software (version 5.04, GraphPad Software, 
La Jolla, CA). The values are shown as mean ± standard deviation (SD) or standard error of 
the mean (SEM). P< 0.05 was considered significant.  
 
Paper III-IV 
Data are presented as frequencies or median (range). Data were analyzed by a 
nonparametric one-way analysis of variance. Spearman’s rank order correlation test was 
used to assess for concordance between the first and second clinical assessments. The 
Mann–Whitney U-test was used to compare groups. The statistical analysis was performed 
using a statistical software package Statistica (Statistica 10; StatSoft Inc, Tulsa, OK, USA). 
P <0.05 was considered statistically significant.  
 
Paper V 
Descriptive statistics were provided for patient-reported occurrence of persistent visible signs, 
and satisfaction with treatment, and for the interrelatedness between these variables and the 
HRQOL dimensions. Continuous variables were presented with median and inter-quartile-
range, and categorical variables were presented as frequencies and percentage.  
HRQOL in the patient group was compared to reference values in Sweden and Europe. One-
sample t-test was implemented to compare the patient groups T-values of HRQOL domains 
to the reference population mean for each domain. 
The impact on HRQOL was measured regarding four continuous variables; age, volume of 
the malformation, total number of treatments, and annual number of treatments, as well as 
five categorical background variables; localization of LM, result of treatment, type of LM, 
and gender. Localization of LM was categorized into two groups; head/neck and other 
localization, results of treatment were categorized into two groups. Group 1, the two best 
categories, and group 2 the four poorest categories. The impact of each variable on the 
HRQOL domain was assessed using ANOVA F-test. Multiple models were not considered. 
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The estimated strength of association between continuous predictors and HRQOL domains 
was presented with Pearson correlation coefficient. Statistical significance was set to p<0.05. 
All analysis was run in R version 3.3.2.[86]  
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4.2 RESULTS 
Expression of TLR4 on monocytes after cell stimulation (Paper I and II)  
 
In the group of patients with good treatment result (HR), with OK-432 there were two boys 
and three girls and in the group with insufficient result (LR) there were two boys and four 
girls. All patients had clinically large malformations with significant psychosocial impact. 
The total size of the malformations and the size of the cysts within the malformation that 
categorizes the type of LM were comparable between the groups. The mean age in the HR 
group was 1.4 ± 0.9 (range 0.5-2.6) y and 2.8 ± 2.9 (range 0.7-7.4) p=0.31. The analysis 
was performed after a mean period of 44 months in the HR group and 49 months in the LR 
group respectively after the end of the treatment. There was no statistical difference 
between the groups. The hypothesis could not be verified with respect to TLR7 expression. 
However TLR4 expression was significantly increased in the group of patients with high 
response after OK-432 treatment. We did additionally observe that malformations with 
similar morphology responded differently after TLR4 stimulation with LPS.  
In Paper I intracellular staining for TLR7 expression revealed a slight mean increase by a 
factor 0.5 in the HR group and a mild decrease by the factor 0.6 in the LR group, respectively 
after LPS stimulation compared with the unstimulated isotype controls. The difference did 
not reach statistic significance. However the expression analysis of TLR4 showed a relative 
increase after LPS stimulation in the HR group by the factor 3.6, which was significantly 
higher than in the LR group (factor 1 compared with nonstimulated isotype controls, 
P=0.037).  
In Paper II prestimulation values of TLR4 expression in the LR group compared with the 
HR group were (950 ± 718 vs. 477 ± 341). Mean MFI after LPS stimulation was 
comparable in both groups (HR 1142 ± 652 units, LR 839 ± 427 units; mean value ± SD; P 
= 0.85). This observation is in accordance with the analysis of the mean absolute 
differences between TLR4 expressions in cells of samples with and without LPS 
stimulation (HR 665 ± 683 vs. LR -111 ± 605; P = 0.08), showing mean down-regulation in 
the LR group. 
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Characteristics of patients with LM and clinical outcome (Paper III) 
Patient characteristics are outlined in Table 3 and compared with data from a similar study. 
Diagnosis was prenatal in five (4%) patients and neonatal in 54 (42%) patients, with 17 
(13%) diagnosed during infancy, 29 (23%) at one to three years of age and 23 (18%) after 
three years of age. External malformations that expanded into the mediastinum and, or, the 
retroperitoneal cavity were encountered in eight (6%) patients. Estimated median volume of 
the lesions was 35ml (range 2-1500). Time from debut of symptoms to confirmation of the 
LM diagnosis was 1.2 years (range 0-21).  
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Table 3 Baseline characteristics of this study compared with Burrows et al ref. Abbreviations: y=years, 
m=months, MacC=macrocystic, MicC=microcystic, Mixed=mixed type.(%) 
 
After OK-432 treatment, symptoms such as local swelling, low-grade fever and redness were 
observed in the vast majority of the patients, but were regarded as expected side effects of the 
treatment. 
Major adverse events such as re-admission to hospital and, or, emergency surgery due to 
major swelling affecting vital functions occurred in five of the patients. All of them had 
 Present study 
n= 131 
Burrows et al (ref) 
n=41 
Age, median (range) 3.4y (2 m-78 y) 6.9y (3 m -31 y) 
F/M 80/58(58/42) 24/17(59/41) 
Location of lesion  
-Head-neck 
-Truncal 
 -Extremities 
 -Combined 
 
79(60) 
26(20)  
  8 (6) 
18(14) 
 
 
27(66) 
   8(19) 
   6(15) 
   0 (0) 
 
Lesion type  
-MacC   (>1 cm) 
-MicC    (<1cm) 
-Mixed 
 
27(21) 
13(10) 
89(69) 
 
20(49) 
  3(7) 
18(44) 
Prior surgical excision   
  5(4) 
 
18(44) 
 40 
mediastinal involvement of the malformation. Delayed extubation (8-17 days) due to airway 
compromise were planned in 15 patients and they were observed post-treatment in the 
intensive care unit. Protective pre-treatment tracheostomy was given to five patients and two 
additional patients received a tracheostomy after repeated failed attempts to wean them off 
mechanical ventilation. All these patients had large cervical or intra-thoracic lesions. We did 
not observe any case of ulceration, scarring, nerve damage or persistent swelling due to the 
OK-432 treatment. In total, 19 patients received surgery, three primarily and 16 after 
unsatisfactory results of OK-432 treatment. Unsatisfactory results of OK-432 treatment were   
considered after a median number of six injection treatments (range 1-11). Of the primarily 
operated patients, two received surgery because of the risk of compromise of the airways. 
Unsatisfactory results from sclerotherapy were the cause for the operation in 12 patients with 
LM involvement of the head/neck region, one on the trunk and three lesions on multiple 
regions. The type of malformation that required an operation due to unsatisfactory results 
from sclerotherapy was microcystic in four cases, macrocystic in one case and mixed lesions 
in 11 cases. The patient with a macrocytic malformation was a newborn girl with a huge extra 
thoracic LM. She underwent a failed attempt of intra-lesional sclerotherapy with ethanol. Her 
general condition improved and she was accepted for OK-432 sclerotherapy. However, that 
treatment also failed and she was successfully operated on. 
 The CAS was worse in one patient, poor in 14, fair in 24, good in 39 and excellent in 53 
patients. The age at first treatment with OK-432 was 3.4 years (0.03-75) and the median time 
to last follow up after the first injection treatment was nine years (1-19). Patients with 
microcystic malformations showed excellent or good results in five out of 13 cases and all of 
them had LM volumes less than 15 cm3 (Table 4).  
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 Number of 
treatments, 
median 
(range) 
Worse Poor Fair Good Excellent n 
MicC 3    (1-9) 0 4 4 3 2 13 
MacC 2    (1-7) 0 1 1 7 18 27 
Mixed 2  (1-12) 1 9 19 29 33       91      
Total 2  (1-12) 1 14 24 39 53      131 
Table 4 Lesion type, number of injections, and outcome. Abbreviations: MicC= microcystic, 
MacC=macrocystic, Mixed=mixed type 
 
Previous OK-432 treatment, resection and, or, another type of sclerotherapy, as well as 
localization to head and neck predicted a less favorable outcome (p=0.008 and p=0.016, 
respectively). Furthermore, four or more injection treatments also predicted a less favorable 
outcome compared to those treated with fewer injections (p=0.0003).  The 29 patients who 
were assessed twice had similar outcomes at both assessments, the first in 2002 and the 
second in 2013. 
 
Mediastinal LM, clinical outcome and complications (Paper IV) 
Between 2009 and 2015 we treated seven patients, five girls and two boys, with LMs 
expanding into the mediastinum. Patient characteristics are summarized in Table 5 and 
complications and outcome is summarizes in Table 6.  
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 Pat 1 Pat 2 Pat 3 Pat 4 Pat 5 Pat 6 Pat 7 
Pre-natal 
diagnosis 
Y N Y N Y N N 
Neo-natal 
diagnosis 
N N N Y N Y Y 
Late diagnosis N Y N N N N N 
Full term Y Y Y Y N Y Y 
EXIT-delivery Y N N N N N N 
Type of LM Mixed Mixed Mixed Mixed Mixed Mixed Mixed 
Cervical 
components of 
the 
malformation 
Y N Y Y N Y Y 
Respiratory 
distress at time 
of diagnosis 
Y Y Y N Y Y N 
Anatomic 
airway 
compromise at 
time of 
diagnosis 
Y  
Lung 
 
Y  
Distal 
trachea 
Y  
Distal trachea 
N Y 
Lung 
Y  
Distal 
trachea 
N 
Circulation 
compromise at 
time of 
diagnosis 
N N N N Y N N 
Primary 
sclerotherapy 
N Y  
OK-432 
0,1 mg x1 
Y 
Sotradecol 
3% 20 mL x1 
N Y 
Doxycyclin 
50 mg x9 
Y 
OK-432 0,1 
mg x4 
Y 
Bleomycin 
6000 IE x3 
 
Table 5 Patient characteristics. Abbreviations: Yes,Y; No,N 
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Table 6 Complications and outcome * Complications according to Clavien-Dindo classification** Premature infant, long 
NICU time due to prematurity, *** Infant with pulmonary hypoplasia requiring long time ventilation support  
 Pat 1 Pat 2 Pat 3 Pat 4 Pat 5 Pat 6 Pat 7 
No of 
complications 
grade 1-2 * 
After primary 
sclerotherapy 
 
Prim surgery 3 4 Prim 
surgery 
4 5 3 
No of 
complications  
Grade 3-5 * 
after primary 
sclerotherapy 
 
Prim surgery 6 7 Prim 
surgery 
11 12 6 
Days in ICU 
after primary 
sclerotherapy 
 31 14  * 9 10 
Number of 
surgical 
procedures 
1 2 2 1 2 2 0 
No of 
complications 
grade 1-2 * 
After surgery 
4 4 4 4 4 Only 
cervical 
excision 
Only sclero 
No of 
complications  
grade 3-5 * 
after surgery 
3 2 1 1 1 Only 
cervical 
excision 
Only sclero 
Days in ICU 
after surgery  
Trach *** 5 8 3 ** Only 
cervical 
excision 
Only sclero  
Time after 
surgery/ sclero 
at last follow-
up 
4,25 y  3,17 y  1,33 y         2,92 y 4,17 y     6,42 y 2,25 y 
Clinical 
assessment 
score (1-5) 
5 5 5 5 5 3 4 
LM in 
mediastinum 
on MRI at last 
follow-up 
Y N N N N Y Y 
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The vast majority of the patients (71%) had respiratory distress when the diagnosis was 
confirmed at postnatal MRI. All patients had predominately macro-cystic LMs with part of 
the malformations containing micro-cystic components, being classified as mixed LMs. 
Airway compromise at the time of diagnosis was common, and was encountered in 57% of 
the patients. Three patients had anatomical compression of the trachea and two patients had 
sub-total compression of the right lung. All three patients with tracheoscopy-verified 
compression to the trachea had compromise of the distal trachea, and a tracheostomy would 
not have been protective. Only one patient was given a pre-treatment protective tracheostomy 
and one patient required a post-operative tracheostomy due to prolonged need of mechanical 
ventilation.  
All patients received sclerotherapy. Five patients were treated with sclerosing agents as first 
line of treatment and two had sclerotherapy as an adjunctive intra- and postoperatively. The 
sclerosing agents and doses used were OK-432 0,1 mg in four patients and bleomycin 6000 
IE, doxycycline 50 mg, and sotradecol 3% 6,5 mL in one patient respectively. Two of the 
patients that were treated with sclerotherapy, were observed at the pediatric intensive care 
unit, PICU, and on mechanical ventilation, until the maximum swelling phase of the 
treatment started to decline. Shortly after discharge, both patients were re-admitted to the 
hospital and to the PICU, due to acute airway obstruction and mediastinal deviation leading 
to compromise of the intra-thoracic circulation. A third patient received a protective 
tracheostomy before sclerotherapy. The tracheostomy did not prevent obstruction on the 
trachea distal to the stoma. The patients treated with sclerotherapy experienced in median 
four (range 2-6) Clavien-Dindo grade I-II complications and in median seven (range 6-12) 
Clavien-Dindo grade III-IV complications. The median time with mechanical ventilation at 
the neonatal intensive care unit (NICU) after each sclerotherapy was eleven days (range 8-
31). There was no difference in post-treatment need of mechanical ventilation and 
observation at the NICU between the different sclerosing agents. Patient 1 and patient 5 are 
excluded from these figures since they were intubated directly after birth and could not be 
weaned off mechanical ventilation before they were operated.  
Five of the patients (71%) were operated with excision of the LM in the mediastinum. The 
operative procedure was done accessing the mediastinum through a median sternotomy. The 
malformation was excised/ de-bulked without sacrifice of vital structures. Intra-operative 
sclerotherapy was administrated to all patients. Intraoperative sclerotherapy after excision of 
the bulk of the malformation was provided to the proximity of the malformation and the 
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excised margins to deeper lymphatic ducts.  Two of the patients were operated primarily and 
three patients were operated after life threatening complications to sclerotherapy. The 
operated patients experienced in median three (range 2-4) Clavien-Dindo grade I-II 
complications and in median two (range 1-4) complications of Clavien-Dindo grade III-IV. 
No patients experienced function loosing surgical complications such as nerve injury or vocal 
cord palsy. One patient required extended post-operative neonatal care at the neonatal 
intensive care unit, NICU, due to prematurity before she could be discharged from the 
hospital, and one patient received a postoperative tracheostomy as she was in need of a 
prolonged ventilatory support due to suspected pulmonary hypoplasia. The remaining three 
patients were operated and were discharged from the Pediatric Intensive Care Unit (PICU) 
after 3, 5, 8 days respectively. No patients were readmitted to the PICU for ventilator support 
after discharge.  
The mean follow-up time was 3,5 years (range 1,3-6,4). The clinical assessment at last follow 
up was excellent for 5/7 patients. Two patients that only received sclerotherapy were assessed 
as good and fair respectively. 
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HRQOL in patients with LM treated with OK-432 (Paper V) 
One hundred and thirty-eight patients had been treated with OK-432 for LM from 1998-2013. 
In 40 patients the follow up from first injection treatment was less than 5 years. Thirty-nine 
patients were less than 8 years of age or older than 18 years of age at follow up.  Forty-nine 
of 59 (83%) patients who were eligible for the study responded to the questionnaires. 
Demographics and background data of the 49 included patients are presented in Table 7. 
 
n     49 
Gender=male (%)    18 (36.7) 
Age at assessment (years, mean (sd))   12.41 (2.87) 
Time from first treatment to assessment (years, median [IQR]) 8.94 [6.84, 11.38] 
Volume of the malformation (ml, median [IQR])  40 [20,100] 
Total number of injection treatments (n, median [IQR]) 3 [2,5] 
Annual number of injection treatments (n, median [IQR]) 0.18 [0.11,0.34] 
Localization, n (%)  
not head-neck   16 (32.7) 
head and neck   33 (67.3) 
Type of malformation, n (%) 
macrocystic    14 (28.6) 
mixed LM    30 (61.2) 
microcystic LM   5 (10.2) 
Patient satisfaction, n (%) 
satisfied    36 (73.5) 
not satisfied    13 (26.5) 
Table 7  Patient demographics and background data 
The results for the KIDSCREEN-52 are shown as T-values in Table 2A and Table 2B. 
Swedish patients treated with sclerotherapy for LM scored higher than the European 
reference values for Autonomy (p=0.014), Financial Resources (p=0.015), School 
Environment (p=0.004) and Bullying (p=0.041). Regarding the other KIDSCREEN-52 
dimensions LM patients did not differ from the European reference values (Table 2A). No 
differences were found between 12-18 years old LM patients and Swedish norm values 
(Table 8). 
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Patient group 
 
Norm values 
SE 
 
Dimensions Mean SD n Mean SD p-value 
Physical Well-being 48.9 8.88 29 48.0 8.88 0.576 
Psychological Well-
being 
48.7 9.94 29 49.5 9.94 0.647 
Moods & Emotions 49.7 11.55 29 49.8 11.55 0.923 
Self-Perception 46.6 9.11 29 49.1 9.11 0.142 
Autonomy 53.4 10.67 29 50.8 10.67 0.196 
Parent Relation & 
Home Life 
51.9 9.06 29 52.2 9.06 0.858 
Financial Resources 54.8 7.92 29 52.3 7.92 0.097 
Social Support & Peers 52.3 11.67 29 51.7 11.67 0.794 
School Environment 53.0 12.43 29 51.3 12.43 0.474 
Bullying 53.7 8.21 29 52.9 8.21 0.623 
Table 8. LM patients, 12-18 years of age, vs Swedish norm values (T-values) for KIDSCREEN-52, 12-18 years. 
The relationship between the continuous variables and the studied HRQOL dimensions are 
shown in Table 9. Statistically significant negative correlations were found between the total 
number of injection treatments and Autonomy (p=0.013), Parent Relation and Home Life 
(p=0.014), Financial Resources (p=0.025), and School Environment (p=0.037). 
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 Correlation p-valuesa 
 Age 
Volu
me 
No of 
inj 
Inj./year Age Volume 
No of 
inj 
Inj./year 
Physical Well-being -
0.13 
0.18 -0.25 -0.16 
0.37
9 
0.234 0.090 0.271 
Psychological Well-
being 
-
0.21 
0.21 -0.18 -0.08 
0.14
3 
0.146 0.212 0.612 
Moods & Emotions -
0.29 
0.00 -0.24 -0.12 
0.04
4 
0.983 0.100 0.424 
Self-Perception -
0.39 
-0.12 -0.07 0.03 
0.00
5 
0.406 0.648 0.845 
Autonomy -
0.03 
-0.21 -0.36 -0.26 
0.82
3 
0.145 0.013 0.073 
Parent Relation & 
Home Life 
-
0.09 
-0.08 -0.35 -0.23 
0.52
6 
0.569 0.014 0.121 
Financial Resources 
0.25 0.21 -0.33 -0.29 
0.09
7 
0.166 0.025 0.056 
Social Support & 
Peers 
-
0.10 
0.07 -0.26 -0.18 
0.50
4 
0.644 0.077 0.225 
School Environment -
0.29 
0.08 -0.31 -0.17 
0.05
0 
0.586 0.037 0.256 
Bullying 
0.12 0.08 -0.09 -0.07 
0.42
0 
0.583 0.562 0.666 
a F-test, two-tailed. 
Table 9 Associations between HRQOL dimensions and age, volume, total number of injections, and injections 
per year 
Outcomes for the categorical variables are shown in Figure 1. Localization in the head neck 
area was a negative predictor throughout all studied dimensions with the strongest correlation 
with Psychological Well-being (p=0.009), Parent Relation and Home Life (p=0.017) and 
School Environment (p=0.006). Less satisfying result of the treatment was also noticed as a 
negative predictor for all HRQOL dimensions (Fig 15). Gender was not a significant 
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predicting variable except for girls in the dimension Mood and Emotions (p=0.034) in 
combination with head-neck localization of the malformation.  
 
 
 
Fig 15  Plot charts for associations between HRQOL dimensions and gender, localization and treatment outcome 
("1-2" = the two best treatment outcome categories; "3-6" = the four poorest treatment outcome categories). 
 
Visible signs of the LM were persistent in 44.9% of the patients. Bivariate analysis indicated 
that persistent visible signs per se were unrelated to HRQOL outcomes. However, patients 
with visible signs were less satisfied with treatment (Fishers Exact Test, p = <0,001). All but 
one, .i.e., 96% of patients with no visible signs were very satisfied with treatment. The 
corresponding portion in patients with persistent signs was 29%. Also, the degree of 
experienced overall difficulty of remaining problems including signs of illness was negatively 
correlated with satisfaction with treatment (r= -0.384, p = 0.011). 
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4.3 DISCUSSION 
 
Dynamic Toll-like receptor expression predicts outcome of sclerotherapy for 
lymphatic malformations with OK-432 in children (Paper I and II)  
The hypothesis that expression of TLR7 would predict outcome of OK-432 treatment could 
not be verified since there were no significant differences between the groups after LPS 
stimulation. This could be explained by the fact that LPS is a selective TLR4-ligand and is 
not primarily directed against TLR7. TLR4 expression was significantly increased in the 
group of patients with high response after OK-432 treatment. This result is consistent with 
the expected enhanced TLR4- dependent immunologic effect in this group compared with 
the LR group. Differential responses to LPS in healthy humans on the basis of common 
TLR4 variants have been described[87, 88].  
It remains elusive if these mechanisms play a role in the present patients. According to 
clinical measures, however, the malformations were comparable. A drawback is the 
analysis of TLR expression after treatment with OK-432. Although the mean period 
between treatment and analysis is at least 44 months in both the groups, an influence of the 
immunostimulatory treatment on the result cannot be fully excluded. A possible influence 
can only be ruled out with a prospective study that gives a chance for an analysis before the 
treatment. We could identify TLR4 as a candidate parameter, which most probably can be 
used to predict the outcome of treatment of LMs with OK-432. However, the observation of 
relative TLR4 expression changes could be explained by two different conditions: either a 
substantial increase of TLR4 expression after LPS treatment or differences of expression 
before treatment with similar expression patterns after incubation with LPS. We showed 
comparably high TLR4 expression values in monocytes of patients with low treatment 
results without relevant differences after LPS stimulation. Treatment results can be possibly 
be predicted on the basis of absolute values before LPS stimulation. 
Although a further explanation was not the scope of the present study with its clinical 
practical approach, it is striking that the mean absolute TLR4 expression after LPS is even 
down-regulated compared with un-stimulated controls in the LR group. Conditions with 
endotoxin hypo-responsiveness are well described[87, 88]. 
The capacity for LPS responsiveness has been shown to be related to the variation of 
individual TLR expression levels[89]. 
In septic patients with primarily enhanced TLR4 expression a ceiling effect without further 
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capacity for enhancement of TLR expression has been described[90]. 
Primarily enhanced TLR4 expression could theoretically limit further TLR up-regulation. 
However, to mimic the long-lasting influence of OK-432 on monocytes in LMs, we 
incubated the cells with LPS in vitro for 20 h. In most published studies investigating TLR 
responsiveness, LPS incubation time is much shorter.  
To supplement previous results of the predictive value of dynamic up-regulation of TLR4 
after OK-432 sclerotherapy, also absolute values appear to be important. Determination of 
thresholds could simplify the prediction of successful treatment with OK- 432. 
 
Clinical outcome of patients with LM treated with OK-432 (Paper III) 
Paper III reports the largest single center experience with OK-432 treatment for LMs. The 
time to follow up was longer than previously reported. The outcome of OK-432 treatment 
was good or excellent in a majority of patients with LM. A few patients with malformations 
involving the mediastinum and abdominal/ retroperitoneal cavities were of special concern. 
All patients requiring emergency surgery had involvement of the mediastinum and, or, the 
abdominal/retroperitoneal cavities (Fig 16). If the LMs affect vital organs, with life-
threatening symptoms, acute operative debulking may be needed. If total excision is not 
possible, complementary sclerotherapy may be mandatory. These malformations often 
require treatment during infancy. This group of patients had major adverse effects of OK-432 
treatment with severe swelling.  
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Fig 16 Magnetic resonance imaging of a retroperitoneal lymphatic malformation. 
 
Surgery used to be the traditional primary treatment modality for LM and it is still 
mandated under special circumstances[63]. It is often difficult to excise these lesions due to 
diffuse infiltration in adjacent tissues and thus high risk of surgical complications[63]. 
Various non-surgical options have been suggested to treat LM, such as radio frequency 
ablation, laser and sclerotherapy with different sclerosing agents. Sclerotherapy is the 
primary treatment modality in most centres[49, 51, 63, 64, 91]. Acevedo et al carried out a 
systematic review of the literature on non-surgical treatment of lymphatic malformations.  
The literature strongly suggests that the majority of patients who undergo sclerotherapy with 
OK-432 or bleomycin as first-line therapy for head and neck LM will achieve a good to 
excellent clinical response. Serious complications and the need to progress to surgical salvage 
were infrequent[48]. 
The patient characteristics of our cohort were similar to those reported from a similar tertiary 
care center. However, compared to the cohort of Burrows et al, mixed lesions were more 
common in our series[50]. 
One explanation could be that our patients were more strictly classified as mixed if the LM 
consisted of both micro cysts and macro cysts. In our cohort, 59% of LMs were diagnosed 
before one-year-of-age and 18% after the age of three. Thus LM is a challenge for pediatric 
healthcare and with better antenatal screening the number of prenatally diagnosed lesions will 
probably increase.  
Our study had limitations due to the heterogeneity of the LM patient characteristics and the 
fact that it is a retrospective study. Multivariate analysis showed a significant negative impact 
on the clinical outcome for only three of the tested variables: previous treatment, lesion 
location and the number of injection treatments. The negative effect on outcome by previous 
treatment, using other sclerosing agents or surgery, was in concordance with previous studies 
and may have been caused by scarring in the tissue induced by other sclerosants[51].  
The location of the lesion predicted unfavorable outcomes, which may be explained by the 
association between head and neck lesions and mediastinal involvement. These LMs are 
prone to airway compromise and compression of major central blood vessels. Furthermore, 
facial lesions often required repeated OK-432 injections with no positive effect on the clinical 
outcome. There was a clear negative correlation between the number of treatments and 
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unfavorable clinical outcome, which might have been expected. More than four injections 
seemed to predict an unfavorable outcome and indicated the need for surgery. Most of the 
patients with macrocystic LMs (n =27) had an excellent outcome as a result of OK-432 
treatment. However, despite similar radiological findings, four of them required more than 
three injection treatments to get optimal results. Five of the 13 patients with microcystic LM 
had a good or excellent outcome. These patients had similar radiological findings but smaller 
lesions compared to those with less favorable outcomes. A similar pattern was seen in the 
group with mixed lesions (n= 91). The type of LM, microcystic, macrocystic or mixed 
lesions, is often considered to be a prognostic factor for the outcome of sclerotherapy[67, 68]. 
The different outcomes in patients with the same type of lesion may indicate that individual 
factors have an influence on the response to the treatment. One explanation for the variation 
in clinical response to OK-432 treatment may be individual immune-pharmacological 
prerequisites[57, 58]. 
In Paper I and II we showed that dynamic TLR-4 expression on monocytes might represent a 
predictive parameter for the response to OK-43 in LMs. The long-term outcome of treatment 
with OK-432 is comparable to short-term outcome. The strength of this study was the fact 
that it was a large consecutive cohort of LM patients receiving care at one tertiary care 
facility by the same pediatric surgeons following the same protocol. MRI is a well-recognized 
method for evaluating patients with LM after sclerotherapy[50]. However, MRI is invasive in 
pediatric patients, due to the need for general anesthesia and it is also expensive. We chose to 
evaluate the patients clinically, using CAS as a follow-up instrument.  CAS as an evaluation 
tool is a cost-effective, non-invasive method of evaluating patients. The clinical findings were 
also the major factor for deciding what treatment the patient should receive.  
 
Treatment algorithm for LM involving the mediastinum (Paper IV) 
Patients with LM involving the mediastinum have a high risk for severe complications 
following sclerotherapy. The swelling is unpredictable and requires extended observation at 
an ICU with ventilation support. Surgical excision of LMs in the mediastinum can be done 
with low incidence of complications[92-94].  
In our group of patients 71% (5/7) had airway obstructive symptoms at the time of 
diagnosis. When the trachea was affected it was evident that the distal part of trachea was 
the most affected part, hence a tracheostomy wouldn't have been protective if additional 
swelling would occur. 
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The management of patients with LM in the mediastinum is complex. A major challenge is 
the timing of the interventions. In our patients airway obstructive symptoms were the main 
indication for intervention. Nonsurgical options for the treatment of LMs, including 
sclerosing agents, aspiration, carbon dioxide laser, and conservative management with 
observation, are widely used. Nevertheless, the multitude of treatment options indicates that 
there is lack of consensus regarding the best therapy for this disease. Sclerotherapy has the 
advantage of being a minimally invasive technique, and it is considered to be the first line 
of treatment for most LMs[35, 49]. 
Three of the patients treated with sclerosing agents in this study experienced severe 
complications with additional swelling compromising vital functions. We tried to tailor the 
sclerotherapy by using different kinds of sclerosing agents (OK-432, bleomycin, 
doxycycline, sotradecol) in order to reduce the risk of complications based on the unique 
characteristics of the substances. Despite this all patients experienced grade IV 
complications according to the Clavien-Dindo classification and required post sclerotherapy 
intensive care in median eleven days (range 8–31). 
In the operated cases the malformation was removed from the mediastinum and it could be 
confirmed that the compression from the trachea or the lungs was released. On last MRI at 
follow-up, 4 of 5 operated patients had no remaining LM in the mediastinum and one 
patient had clinically insignificant micro-cystic rests remaining. The two patients that only 
received sclerotherapy both had remaining rests of the malformation in the mediastinum 
surrounding vital structures. There is a clear advantage for the operated patients as the risk 
of obstruction of the airways or compression of the central vessels is anatomically removed 
and hence the need of monitoring and follow-up is reduced in comparison to patients 
treated with sclerotherapy. 
The Clavien-Dindo classification system has been showed to be an excellent tool for 
systematic evaluation of complications after surgery[82]. 
The decision of which treatment modality a patient should receive must be made based on 
the best possible outcome with the least degree of severe complications. Thus it is of 
highest importance to evaluate different treatment modalities with the same classification 
system. 
We showed that patients treated with sclerotherapy and operated patients had comparable 
number of mild complications; Clavien-Dindo grade I-II complications. However, severe 
complications, Clavien-Dindo grade III–IV, were more common after sclerotherapy 
  55 
(median seven, range 6–12) than after surgery (median two, range 1–4). 
Surgery has limitations and must be cautiously planned not to jeopardize vital structures. 
Several authors suggest surgery as a safe and feasible strategy in the treatment of LM[93, 
95, 96]. 
Thoracoscopic resection of intra-thoracic LMs can be feasible and reasonable for surgeons 
with advanced laparoscopic skills[95]. 
Although it is feasible to resect intra-thoracic LM with thoracoscopic approach it remains to 
be properly evaluated if the minimally invasive technique adds advantages to the surgically 
treated patients. In our group of patients we noticed a longer ICU time after sclerotherapy 
(median 11 days, range 8–31) than primary surgery (Median 5 days, range 3–8). The 
patients with sclerotherapy also required several treatments (median 3, range 1–9). 
Prolonged PICU care is associated with complications such as septicemia, pneumonia and 
thrombosis associated to central venous catheters[97]. 
These complications must also be a consideration when managing this group of patients. 
Based on our experience in managing these challenging cases, we suggest a treatment 
algorithm for cervical LMs shown in Fig 17. This algorithm is an attempt to guide in the 
decision-making when dealing with these rare malformations. 
 
Fig 17 Treatment algorithm for LM involving the mediastinum 
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LM in the head-neck area that require several treatments are prone to have affected 
HRQOL (Paper V) 
Children and adolescents with LMs report similar HRQOL as the general population of the 
same age and gender. However, compared to the other patients, those with a head-neck 
localization of the malformation, and those with a poor treatment result presented lower 
HRQOL in all dimensions. Also, a high number of treatments was a negative predictor 
regarding HRQOL. These findings indicate that patients with visible and potentially 
psychosocialy stigmatizing LMs that require several treatments represent a risk group for an 
affected HRQOL. Similar studies concerning HRQOL in patients with LM in the head and 
neck region are rare, and this study of Swedish patients is therefore an important 
contribution to this field. We found KIDSCREEN-52 to be a useful tool in the extensive 
evaluation of HRQOL dimensions. HRQOL has previously been studied in children with 
other serious conditions such as type 1 diabetes mellitus and cancer[98-100]. Childhood 
cancer survivors reported HRQOL outcomes that mostly parallel those of matched or non-
matched healthy comparisons[98, 101]. However, certain diagnostic subgroups have been 
found to have impaired HRQOL. Diabetes patients, female sex, poor treatment adherence and 
certain family factors were associated with affected HRQOL[100]. To some extend findings 
regarding HRQOL among vascular malformation patients diverge. Some studies show that 
patients with vascular anomalies, or other rare diseases, despite treatment outcome, have an 
increased risk of physical and psychological undesirable long-term consequences[77-80]. 
However, in the limited information the literature concerning HRQOL in LM or VM patients, 
some studies imply that the HRQOL is not affected[102, 103]. Two Finnish studies report 
HRQOL in VM and LM patients. One of these addressed VM localized to head/neck and 
included 20 patients evaluated after endovascular sclerotherapy[103]. 
Assessments included a 20-item quality of life measure. Quality of life outcomes were found 
to be generally positive, and paralleled to those of aged-matched general population 
individuals. Quality of life varied with localization of VM, and patients of lower age at 
treatment start (<16 years), and patients clinically followed by physicians specialized in VM 
had a better quality of life. Also, the results from the other Finnish study, which surveyed 
quality of life after head/neck or trunk localized LM treatment, indicated positive quality of 
life outcomes[81]. 
In our study, patients reported slightly higher HRQOL compared to the European reference 
values, while there were no difference in comparison to the Swedish reference data. This 
particular finding could possibly to some extent be explained by the fact that previous 
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studies have shown that Swedish population report higher mean values in KIDSCREEN sub-
dimensions, physical well-being excluded, than the European reference population[104].  
We included all patients with the diagnosis of LM. The median size of LM in the cohort was 
40 ml, which means that the size of the malformation in most patients was fairly small. 
Hence, the influence on the HRQOL could be expected to be limited. However, multiple 
treatments with sclerotherapy was shown to be associated with lower HRQOL outcomes in a 
number of sub-dimensions. Although our findings indicate that small malformations can be 
expected to have limited influence on HRQOL, multiple treatments tend to affect the quality 
of life negativly. These findings support previous observations that patients requiring 
multiple treatments report worse quality of life than patients treated with fewer treatment 
sessions[81]. 
A clinical implication of the findings of this study is that small malformations prone to 
several sclerotherapies should be considered for alternative treatment such as surgical 
excision. 
A limitation related to the assessment of HRQOL in this group of patients was the fact that 
the patients in many cases were treated at the age of 3-8 years, and followed up as late as 
five years later. The passing of time could be a contributing explanation to the seemingly 
limited impact on the main HRQOL outcomes. Time might play a role for restoring HRQOL 
after a possible early negative impact of illness on quality of life among these patients. 
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4.4 CONCLUSIONS 
 
Paper I and II 
The capacity of up-regulation of TLR-4 on monocytes after exposure to the TLR4 ligand 
LPS represents a predictive parameter for the outcome of treatment of lymphatic 
malformations with OK-432.  
Patients with low response to OK-432 treatment had high TLR4 expression values in 
monocytes without differences after LPS stimulation. Treatment results can possibly be 
predicted by absolute values before LPS stimulation. 
 
Paper III 
OK-432 sclerotherapy is safe and results in successful outcome in 70% of patients with 
lymphatic malformations. The long-term outcomes are comparable to short-term outcomes.  
Malformations involving the mediastinum and abdominal/retroperitoneal cavities are of 
special concern with an increased risk of compromise of the airways or the digestive tract and 
should be considered for primary surgery.  
A significant negative impact on the clinical outcome for previous treatment, lesion located to 
head-neck area and the number of injection treatments. More than four injections seem to 
predict an unfavorable outcome and indicate the need for surgery.  
CAS as an evaluation tool is a cost-effective, non-invasive method of evaluating patients.  
 
 
Paper IV 
Patients with LM involving the mediastinum have a high-risk for severe complications 
following sclerotherapy.  
The complications after surgery as well as sclerotherapy could by analyzed according to 
Clavien-Dindo classification for postoperative complications. Severe complications, 
Clavien-Dindo grade III–IV, are more common after sclerotherapy than after surgery  
The swelling after sclerotherapy is unpredictable and the treatment requires extended 
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observation at an ICU with ventilation support.  
Tracheostomy does not prevent the risk for tracheal compression in mediastinal LM.  
We recommend surgical resection of the LM in the mediastinum, with the possibility of 
intra-operative sclerotherapy as an adjunctive. Surgical excision of LMs in the mediastinum 
can be done with low incidence of complications. 
 
Paper V 
HRQOL in patients with LMs is similar to standardized population norms.  
Patients with LM localized in the head and neck area requiring multiple treatments constitute 
a risk group for affected HRQOL and was shown to be associated with lower HRQOL 
outcomes in a number of sub-dimensions. Multiple treatments per se imply a risk for 
HRQOL impairment.  
A clinical implication of the findings of this study is that small malformations prone to 
several sclerotherapies should be considered for alternative treatment such as surgical 
excision. 
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5. FUTURE PERSPECTIVES 
 
In modern medicine several specialties narrow and specialist focus on smaller details as the 
knowledge within the fields expand. A consequence of this evolution is that gaps in 
knowledge may occur in between the focus areas. A need of a helicopter perspective unifying 
all knowledge and closing the gaps emerge. The field of vascular anomalies remains to be 
further explored. The entity involves a variety of rare congenital vascular lesions that may 
occur in all part of the body and require multi-disciplinary cooperation’s. It is essential that 
cross-national as well as international societies such as ISSVA, NSVA (Nordic Society for 
the study of Vascular Anomalies) and the VascERN (Vascular European Reference Network) 
with representatives from all involved specialities continue the work of making consistency 
regarding the nomenclature in order to facilitate for clinicians and scientists across this 
wide field to communicate using a common language specific for each entity. 
 
In my future scientific work I will continue with two epidemiological studies.  
The first study will be a population-based case-control study consisting of all children born in 
Sweden during the study period from1/1 1973 to 31/12 2014 according to the Medical Birth 
Register. The cases will be identified in the National Patient Register and consists of all 
children with lymphatic malformations in the study cohort. Controls will be randomly 
selected from the cohort without lymphatic malformations (5 controls per case) matched for 
sex and year of birth. The following maternal risk factors will be analyzed; maternal age, 
maternal BMI, mother´s medical history, smoking and medications. The perinatal 
demographics that will be studied are; the place of birth, twin pregnancy, gestational age, 
birth weight, birth height, and associated malformations in the baby. The data received will 
be completely anonymous. The association between exposure and risk will be analyzed. 
Adjustment for potential confounders will be performed. The incidence of lymphatic 
malformations per number of live births will be calculated for each calendar year. 
 
The second study will be a register study with data from the Medical Birth Register, Patient 
Register, the Register for Prescribed Medicine, the Cancer- and Cause of death Register. This 
will be a cohort study, which consists of all children born with lymphatic malformations from 
1/1 1964 to 31/12 2014 according to the Medical Birth Register and the National Patient 
Register. Data on associated diseases will be collected from the Patient Registry, Cancer 
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Register, Cause of Death Register and the Register for Prescribed Medicine. Register data are 
linked using the social security number. The received data will be completely anonymous. 
Data will be analyzed for various diseases and their prevalence in patients with lymphatic 
malformations. Medication may be an indication of a disease. Controls will be randomly 
selected children from the cohort without lymphatic malformations (5 controls per case) 
matched for sex and year of birth. 
Epidemiological register studies do have special ethical reflections. Register studies in 
Sweden do not mandate written informed consent. From the researchers point of view it is 
obvious that many register studies wouldn’t be possible to perform if the legislation would 
change since many register studies are so extensive which prohibits the possibility to inform 
each individual in the study and receive written consents. However, as a scientist one must 
know that the received data, in spite of being anonymous to the investigators, may be linked 
to specific individuals and should thus be protected and handled as classified information.
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6 POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ SVENSKA 
 
Lymfatiska missbildningar (LM) definieras som strukturella fel i lymfkärlen som uppstår 
på grund av defekt fosterutveckling av lymfkärlen. Förekomsten av dessa missbildningar är 
svår att ange i exakta siffror. I litteraturen varierar uppgifter om förekomsten mellan 1: 
6000 till 1:16.000 levande födda.  
Orsaken till LM är multifaktoriell. Genetiska studier visar mutationer i somatiska gener så 
som PIK3CA-genen vara associerad med förekomsten av LM. 
Histologiskt är LM godartade, men beroende på lokalisation, storlek och oväntad svullnad 
kan de orsaka allvarliga komplikationer som hotar vitala funktioner i kroppen så som 
exempelvis luftvägarna eller synen. En stor svullnad i ansikte eller på halsen kan också 
påverka estetiken och på så vis utgöra en psykologisk belastning för patienterna och deras 
familjer. LM är mycket immunreaktiva och är benägna att återkommande bli infekterade. 
De kan lätt bli inflammerade och orsaka smärta samt kroniska läckande sår. Vissa 
anatomiska regioner så som brösthålan (mediastinum) är extra bekymmersamma. En 
plötslig svullnad i mediastinum som utgörs av ett begränsat hålrum med vitala strukturer så 
som luftvägarna, de stora kärlen och hjärtat kan lätt leda till livshotande komplikationer. 
Det finns inte tillräckligt med vetenskapligt underlag för att skapa en tydlig 
behandlingsalgoritm för handläggandet av LM. Kirurgi har tidigare ansetts som första 
behandlingsalternativet. Kirurgi har dock sina begränsningar då dessa missbildningar ofta 
infiltrerar intilliggande strukturer, såsom kärl och nerver. Det gör att total resektion blir svår 
och potentiellt farligt. Perkutan skleroterapi har ersatt kirurgi som förstahandsbehandling i 
de flesta fall. Skleroterapi har dock också sina begränsningar och kan orsaka allvarliga 
komplikationer så som svullnad som påverkar vitala funktioner och ärrbildning. 
I denna avhandling sökte vi svaret på ett antal essentiella frågor om patienter med LM. Vi 
ville ta reda på hur det har gått för patienterna över en långtids uppföljning både avseende 
kliniskt behandlingsresultat och komplikationer såväl som påverkan på livskvalitet. Vi ville 
utvärdera injektionsbehandlingar och kirurgi som behandling både individuellt men också 
inbördes i avsikt att skatta behandlingsresultat och komplikationer från de olika 
behandlingsmetoderna bedömda med samma utvärderingsinstrument.  
Målsättningen med delarbete I och delarbete II var att studera den immunologiska 
reaktionen efter behandlingen av lymfatiska missbildningar med OK-432. Med ökad 
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förståelse för den ville vi identifiera en mätbar parameter för att kunna prognostisera utfallet 
av behandlingen och på så vis kunna etablera en riktlinje för val av behandlingsmetod. Vår 
hypotes var att OK-432 aktiverar immunförsvaret genom att vara en ickeselektiv agonist till 
Toll-Like receptor-4 (TLR-4). Vid en aktivering av TLR-4 sker en uppgradering dels av 
TLR-4 men också TLR-7. Vid en uppgradering av TLR-7 sker en mer potent immunrespons. 
Vi analyserade 11 barn som behandlats med OK-432 för lymfatisk missbildning. Sex barn 
med icke tillfredställande behandlingsresultat (LR) och fem med bra behandlingsresultat 
(HR). De två grupperna hade jämförbara missbildningar utifrån radiologisk diagnostik. De 
två grupperna jämfördes avseende monocyternas förmåga till uppreglering av TLR-4 efter 
20h stimulering med Lipopolysaccharid (LPS). LPS är en vedertagen selektiv TLR-4 agonist 
och aktiverar immunförsvaret i det avseendet på samma vis som OK-432. Vi mätte därefter 
monocyternas uppreglering av TLR-4 och TLR-7 med Flourescence Activated Cell Sorting 
(FACS). P<0.05 ansågs som statistiskt säkert. 
I delarbete I fann vi att medeluppregleringen av TLR4 efter LPS stimulering var statistiskt 
högre i gruppen som haft bra behandlingsresultat (HR) P=0.037).  
I delarbete II fördjupade vi analyserna från arbetet i delarbete I. Vi analyserade om absoluta 
värden på TLR4 förekomst på monocyter skulle kunna förutsäga patienternas behandlings 
resultat efter behandling med OK-432. 
Vi studerade absoluta värden av TLR-4 på monocyter innan och efter LPS stimulering. De 
totala TLR-4 värdena efter LPS stimulering var jämförbart i båda grupperna (HR 1142 ± 652 
enheter, LR 839 ± 427 enheter, P = 0.85). Pre-stimuleringsvärden i LR gruppen i jämförelse 
med HR gruppen var 950 ± 718 vs. 477 ± 341. Vi noterade betydande skillnader av 
förändringen i medel expression av TLR4 efter LPS (HR 665±683vs.LR-111±605,P=0.08). 
Vår tidigare observation i delarbete 1 om en nedsatt uppreglering av TLR4 på monocyter 
efter LPS stimulering i LR gruppen i jämförelse med HR gruppen kan förklaras med TLR 
prekonditionering. Detta innebär att patienter med LR har en förhöjd tidigare uppreglering av 
TLR-4 på monocyterna och på så vis blir uppregleringen mindre efter ytterligare stimulering. 
Denna observation innebär att absoluta värden med definerade tröskelvärden av TLR-4 skulle 
kunna prognostisera behandlingsutfall. 
I delarbete III gjorde vi en systematisk genomgång i en retrospektiv journalstudie av alla 
patienter som behandlats med OK-432 på ALB under perioden 1998 till 2013. Resultatet av 
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behandlingen utvärderades kliniskt samt genom en enkät. Vi ville klargöra den generella 
demografin av patienter med LM i denna cohort samt utvärdera lång-tidsresultatet.  
131 av 138 patienter mötte inklusionskriterierna. Den lymfatiska missbildningen var 
lokaliserad till huvud och hals regionen (60%), bålen (20%) och till extremiteterna (6%). 
Missbildningen förekom på flera lokalisationer i 14% av fallen. Majoriteten (69%) av 
patienterna hade mixed LM, 10% hade microcystisk LM och 21% hade macrocystisk LM. I 
median fick de olika missbildningstyperna 3, 2 och2 behandlingar respektive. Median åldern 
för första behandlingen var 3,4 år. Bra eller utmärkt behandlingsresultat uppnåddes av 70% 
av patienterna. Antalet behandlingar, tidigare behandlingar och anatomisk lokalisation i 
ansikte var negativa prognostiska indikatorer. Långtidsresultatet var jämförbart med 
korttidsresultatet. 
Målsättningen med delarbete IV var att utvärdera vår erfarenhet av patienter med lymfatisk 
missbildning som engagerar mediastinum och föreslå en behandlingsalgoritm för stöd i 
handläggandet av denna ovanliga missbildning.  
Detta var en deskriptiv journalgranskning av alla patienter med lymfatisk missbildning med 
engagemang av mediastinum som behandlats på ALB mellan 2009 och 2015. Vi analyserade 
data från patienterna avseende demografi, utredning- och behandlings uppgifter, 
komplikationer till behandling och behandlingsutfall vid uppföljning. Komplikationer 
definierades och bedömdes enligt Clavien-Dindo klassifikationen. Det kliniska 
behandlingresultatet bedömdes på en 4 gradig skala (Excellent-Good, Fair-Poor) 
Kohorten bestod av sju patienter. Alla patienter fick injektionsbehandling. Fem patienter 
opererades, två opererades primärt och tre opererades efter allvarlig komplikation efter 
injektionsbehandling. Patienter som behandlats med injektions behandling och de opererade 
patienterna hade jämförbart med milda komplikationer, Clavien-Dindo grad I-II 
komplikationer. Allvarliga komplikationer, Clavien-Dindo grad III-IV, observerades fem 
gånger mer efter injektionsbehandling jämfört med kirurgi. Det kliniska behandlingsresultatet 
var genomgående "excellent" för de opererade patienterna och "Fair-Good" för de som endast 
fått injektionsbehandling.  
Målsättningen med delarbete V var att beskriva HRQOL (Health Related Quality Of Life) 
hos en lång-tidsuppföljd kohort av patienter med lymfatisk missbildning.  
Alla patienter som behandlats med sklerosering för lymfatisk missbildning på Karolinska 
universitetssjukhuset under perioden 1998-2013 ingick i en retrospektiv journalgenomgång. 
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En för denna studie specifik enkät skickades ut till alla patienter som hade en uppföljning på 
minst fem år med frågor om kvarvarande symtom och nöjdhet med behandling och 
omhändertagandet. KIDSCREEN-52 användes för evaluering av HRQOL. KIDSCREEN-52 
är ett validerat instrument för att utvärdera samtliga dimentioner av HRQOL. 
Fyrtionio av 59 (83%) patienter som mötte studiens inklusionskriterier svarade på enkäten 
och togs med i studien.  Det var statistisk relevant negativ korrelation mellan totalt antal 
injektionsbehandlingar och Autonomy (p=0.013), Parent Relation and Home Life (p=0.014), 
Financial Resources (p=0.025), och School Environment (p=0.037). 
Lokalisation av missbildning i huvud och hals regionen utgjorde genomgående en negativ 
prediktor på samtliga HRQOL parametrar med den starkaste korrelationen med 
Psychological Well-being (p=0.009), Parent Relation and Home Life (p=0.017) och School 
Environment (p=0.006). Otillfredställande resultat av behandlingen noterades också som en 
genomgående negativ prediktor på samtliga HRQOL parametrar.  
Patienter med synliga tecken på missbildning uppvisade en icke statistiskt säkerställd tendens 
att vara mindre nöjda med behandlingen (p=0.155). Graden av upplevda besvär av 
kvarvarande missbildning inklusive synlig missbildning var negativt korrelerat med den 
övergripande nöjdheten med behandlingen (r=0.384, p=0.011). 
 
De huvudsakliga slutsatserna i de fem delarbetena är:  
1. Monocyters förmåga att uppreglera TLR-4 efter LPS stimulering är en positiv prognostisk 
och mätbar parameter för ett tillfredställande behandlingsresultat av LM med OK-432. 
2. Monocyter kan på grund av tidigare stimulering av TL4-agonister ha en uppgradering av 
TLR-4 och på så vis mattas immun responsen av. Höga pre-stimuleringsvärden av TLR-4 
förekomst på monocyter utgör således en mätbar och negativ prognostisk faktor. 
3. Antalet behandlingar med sclerosering, tidigare behandlingar och anatomisk lokalisation i 
huvud och hals regionen var negativa prognostiska indikatorer. Långtids resultatet var 
jämförbart med korttids resultatet. Fyra icke tillfredsställande scleroseringar bör utgöra 
gräns för beslut till alternativ behandling så som exempelvis kirurgi. 
4. Patienter med lymfatisk missbildning som engagerar mediastinum utgör en risk grupp för 
att få allvarlig komplikation efter sclerosering. Svullnaden är oförutsägningsbar och 
kräver lång observationstid på intensivvårdsavdelning med mekanisk ventilation. 
Tracheostomi kan inte skydda luftvägarna vid svullnad i mediastinum. Kirurgisk excision 
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av lymfatisk missbildning i mediastinum rekommenderas med möjlighet till intraoperativ 
adjuvant injektionsbehandling. 
5. LM patienter har jämförbar HRQOL som befolknings normdata. Patienter med 
missbildning i huvud- och halsregionen som behöver multipla behandlingar utgör en 
riskgrupp för att få negativ påverkan på HRQOL parametrar. Multipla behandlingar i sig 
utgör en risk för påverkad HRQOL. 
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